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The mucosal surfaces of the lung and intestinal tract are areas at which 
heterogeneous immune populations must function in concert to maintain barrier integrity 
and coordinate appropriate responses to both pathogenic and innocuous antigens.  The 
Interleukin-17 (IL-17) family member IL-25 is a cytokine associated with allergy and 
asthma which functions to promote type 2 and suppress alternative inflammatory 
responses in epithelial tissues.  This study identifies the IL-25 receptor, IL-17RB, as an 
important mediator of both innate and adaptive type 2 immune responses in the context of 
allergic airways disease and respiratory viral infection.  Through a series of animal 
models, genetic manipulations, adoptive transfers, and a comprehensive characterization 
of IL-25 responsive myeloid populations, we have identified a novel granulocytic 
population of innate IL-25 responsive cells involved in the pathogenesis of allergic 
asthma.  This population, termed Type 2 Myeloid (T2M) cells, produces the type 2 
cytokines IL-4 and IL-13, is recruited in large numbers to the lung in response to IL-25 
secretion, and induces IL-25 associated immunopathology in the airway.  Our findings 
also indicate that T2M cells may be of significant clinical importance.  High dose 
dexamethasone administration, the front line therapy for severe allergic asthma 
exacerbations, did not reduce cytokine production in, or total numbers of, T2M cells.  
Finally, a clinical study using peripheral blood drawn from atopic asthmatic volunteers 
identified a similar IL-4 and IL-13 producing granulocytic population that was not 
 xii 
observed in non-atopic volunteers.  The identification of a novel, pathologically relevant 
granulocytic subset offers an important new avenue for research investigation with the 








The generation of an effective adaptive immune response requires different 
strategies to cope with intracellular (type 1) versus extracellular (type 2) pathogens.  
Atopic asthma is characterized by a heterogeneous influx of inflammatory cells in which 
the type 2 inflammatory response has been co-opted to attack otherwise innocuous 
environmental allergens1.  The hallmarks of chronic allergic asthma; airway 
hyperresponsiveness, bronchiole smooth muscle hypertrophy, and mucus hypersecretion, 
are caused by excessive type 2 cytokine production2,3. 
Interleukin (IL)-25 is a cytokine associated with a variety of type 2 diseases 
which functions to promote type 2 and suppress alternative inflammatory responses4-10.  
IL-25 is produced by the respiratory epithelium in response to noxious stimuli7, as well as 
by inflammatory cells recruited to the airway11-14.  It has been linked to asthma and 
asthma-like sequelae4,5,7,10,15, and represents a potential therapeutic target for the 
treatment of allergic airways disease16.  The cellular targets of IL-25 have been the focus 
of several recent investigations, the results of which have begun to illustrate an integral 
relationship between IL-25 and the development of both innate and adaptive immune 
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responses4,5,10,11,17-19.  The search for IL-25 responsive cells has also led to the 
identification of several previously unrecognized innate immune populations, known 
collectively as innate lymphoid cells20-23.  These discoveries offer some insight into the 
complex regulatory environment associated with type 2 inflammation, and highlight the 
importance of innate populations in the establishment and maintenance of type 2 
immunity. 
The composition of IL-25 responsive cells in the lung, and their relative 
contributions to type 2 diseases such as allergic asthma, remains an area of active study. 
The investigation of IL-25’s role in the pathogenesis of type 2 lung pathologies, including 
allergic asthma and viral exacerbations of underlying asthmatic disease, may enable the 
identification of previously unrecognized components of the inflammatory cascade.  
Refining our understanding of IL-25–mediated biology will provide greater insight into 
mechanisms of allergy that mediate disease phenotypes which present challenges in both 
clinical stratification and effective treatment of asthma, a disease currently without 





 Asthma is a chronic pulmonary disease characterized by episodic symptoms of 
airway obstruction, including shortness of breath, wheezing, and cough24,25.  It represents 
a complex, multifactorial syndrome influenced by a variety of intrinsic and extrinsic 
factors with variable clinical presentations.  The symptoms of asthma are intimately 
linked to physiologic changes associated with its pathogenesis, including airway 
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hyperreactivity, mucus hypersecretion, hypertrophy of bronchiole smooth muscle, and the 
recruitment of inflammatory cells to affected airways1. The most common triggers of 
asthma symptoms are environmental allergens, with atopic asthma accounting for 
approximately 75% of all asthma diagnoses26,27.  Chronic exposures to allergens or other 
noxious stimuli serve to induce inflammatory responses that manifest clinically as an 
asthma attack. 
 Asthma and its associated sequelae represent a significant disease burden that 
affects 9% of all Americans and up to 300 million people worldwide26,28,29, making 
asthma the most common chronic lung disease.  From 2005–2009, annual asthma-related 
hospitalizations and deaths in the United States alone were approximately 500,000 and 
3,500, respectively25, with over 250,000 annual deaths worldwide26,30.  The Centers for 
Disease Control (CDC) reports that almost half of the 25 million Americans with asthma 
have experienced an attack in the past year, and the prevalence of asthma has increased in 
children from 3.6% in 198029 to almost 10% in 200925.  The total healthcare cost 
associated with the disease is also rising, reaching $56 billion in 200724, a 16% increase 
over just 5 years26.  
Multiple factors influence asthma’s increasing prevalence, and it is clear that 
effective management strategies must be adopted in order to lower both the incidence of 
asthma and the frequency at which asthmatic individuals suffer exacerbations of their 
disease.  The most common therapeutic approach to asthma employs a combination of 
pharmacotherapy and the use of an Asthma Action Plan24,31.  In general, basic 
medications include a daily inhaled corticosteroid and a short acting beta-2 agonist, a 
“rescue” medication for bronchospasm that relaxes airway smooth muscle24.  An Asthma 
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Action Plan is a strategy developed between a patient and his or her physician to address 
how the patient should react when symptoms occur, in order to minimize the incidence of 
full-blow asthma attacks and to identify when medical intervention is necessary. 
While a combination of medications and education offers an effective approach to 
the management of most asthmatics’ symptoms, a subset of individuals (in some studies 
up to 10% of all asthmatics) with severe disease have symptoms refractory to oral 
glucocorticoid treatment32-35.  Effective treatment options for these patients, known as 
steroid resistant asthmatics, remain very limited34,36.  A better understanding of the 
biology underlying steroid-resistance is needed to develop new therapies to help patients 
cope with disease, including a more complete understanding of the pathogenesis of the 
pulmonary inflammation that leads to the symptoms of asthma. 
 
Etiology 
Factors influencing the severity of asthma may be associated with its mode of 
development, frequency of exacerbation, or both24.  The multifactorial nature of the 
disease, and the complex interplay between genetic and environmental factors in its 
pathogenesis, make the identification of a single “causative” factor impossible29.  
However, investigations of heritable and environmental risk factors associated with 
asthma have identified several contributing elements.  These include genetic 
susceptibility loci, the adoption of “Western” diets, the “hygiene hypothesis,” increased 
exposure to indoor allergens, air pollution and tobacco smoke, the incidence of 




 Monozygotic twin and familial studies offer evidence for the heritability of 
asthma and suggest that between 40–60% of asthma-associated symptoms have some 
genetic basis37-39.  Owing to asthma’s multifactorial nature, any predisposition to asthma 
is likely the result of epigenetic mechanisms40, polygenic inheritance, and locus 
heterogeneity27,41 (i.e. the sum effects of many different genes in different individuals 
may result in similar clinical phenotypes).  Furthermore, although candidate gene 
analyses have identified more than 100 genes associated with asthma, few of these 
studies have been successfully replicated42.  Unbiased asthma-associated GWAS analyses 
of almost 20,000 individuals43 have identified several asthma-associated loci, however 
the predictive value of these data are low and there is currently little data linking 
genotypes identified by GWAS and variance of clinical phenotype42.  Roughly 40% of all 
children with asthmatic parents will go on to develop asthma26, and maternal asthma 
significantly increases those odds relative to paternal asthma44.  However, genetics alone 
cannot explain the rapid rise in asthma’s prevalence in some populations over the past 
few decades, and further investigation is required to determine the relative contributions 
of various genetic and epigenetic factors45. 
 
Diet and exercise: 
 The increasing incidence of asthma has marched in parallel with an increase in 
obesity for at least 30 years.  Although the correlation is not absolute, obese individuals 
exhibit higher rates of asthma than the general population46,47, and sedentary lifestyles 
(associated with both obesity and asthma), have increased as rates of physical activity 
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have decreased.  Changes in dietary composition, specifically increases in highly 
processed foodstuffs with n-6 polyunsaturated fatty acids (omega-6 PUFA) and decreased 
consumption of antioxidants and n-3 PUFA (also known as omega-3 fatty acids), have 
been associated in cross-sectional studies with an increase in asthma rates48,49.  Overall, 
data linking this type of “fast food” diet to asthma suggest an association but are not 
definitive.  Connections have also been made between maternal diet, breast-feeding, and 
the development of childhood asthma50-54.  Breast–fed children of mothers who consume 
diets high in antioxidants, including vitamin E and zinc, are less likely to develop asthma 
than mothers with low antioxidant consumption, whereas children whose mothers 
consumed diets high in n-6 PUFA while the child was in utero have an increased 
incidence of allergic rhinitis at 5 years of age50,51,55.  These data support the hypothesis 
that diet can be either positively or negatively associated with atopic risk. 
 
The Hygiene Hypothesis 
Few prospective studies to date have focused on the natural history of asthma, 
however worldwide prevalence rates indicate that asthma is largely a disease of the 
developed world26.  As developing nations in Latin America, Eastern Europe, and Asia 
improve public health infrastructure, for example by creating reliable supplies of drinking 
water and improved sanitation, rates of asthma (especially among children) have 
invariably increased28,29. 
These data beg the question as to why allergic diseases have increased in 
industrialized societies, while their prevalence has remained relatively constant in the 
developing world.  More than 20 years ago, Strachen proposed what has come to be 
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known as the “Hygiene Hypothesis” to describe the inverse relationship between the 
number of siblings in a family, birth order, and the incidence of hay fever56.  His original 
work concludes: 
Over the past century declining family size, improvements in household 
amenities, and higher standards of personal cleanliness have reduced the 
opportunity for cross infection in young families.  This may have resulted in more 
widespread clinical expression of atopic disease, emerging earlier in wealthier 
people, as seems to have occurred with hay fever. 
 
While a direct link between Strachen’s initial hypothesis and the development of allergic 
disease has not been established, evidence that exposure to potential allergens is an 
important component in the development of immunologic tolerance has been born out in 
multiple studies by several researchers57-59.  Taken together, these studies indicate that 
tolerance to environmental antigens is improved by increasing exposure to a diverse 
range of stimuli, and that decreasing childhood exposures to potential allergens may limit 
the development of tolerance and increase the odds of allergen sensitization among 
individuals with other risk factors for atopy. 
 
Indoor allergens and environmental irritants 
The most common triggers for allergic asthma are indoor allergens, including 
house dust mite (HDM), cockroach allergen (CRA), pet dander, and mold60-62.  Early 
exposure to these and other allergens is associated with the development of childhood 
asthma63.  For example, increased serum levels of HDM–specific IgE as early as age 2 
are predictive of persistent wheezing by age five64,65.  Allergens with protease activity 
such as HDM and CRA are particularly potent because they can also stimulate 
inflammatory cells directly by binding to protease-activated receptor 2 (PAR-2), further 
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exacerbating the allergic response66.  Several studies have reported a correlation between 
the increased exposure to indoor allergens and the development of asthma63.  Others have 
found that while the risk of sensitization to specific allergens increases with increasing 
exposure, the overall incidence of atopy is not significantly increased67.  Thus, 
individuals predisposed to an atopic phenotype are at greater risk of becoming sensitized 
to commonly encountered environmental allergens, however increased exposure does not 
necessarily represent a nidus for the development of allergic asthma in the general 
population.  Therefore, while indoor allergens are the most common triggers for atopic 
individuals and the pathogenesis of allergic asthma is associated with these stimuli, 
allergens in and of themselves are not causative agents.  It is more likely that a 
combination of genetic and environmental factors foreshadows the likelihood of 
sensitization to one or more allergens, and atopic individuals develop sensitivities to 
those allergens to which they experience the most consistent exposure67. 
 Another common set of asthmatic triggers is air pollutants; including tobacco 
smoke and diesel exhaust particles (DEP)29,68-70.  Exposure to these chemical irritants in 
infancy, early childhood, and even in utero, is associated with an increased risk of 
asthma58,71-73.  Biomass fuels (BMFs), the most common source of fuel for cooking and 
heating in much of the developing world, also represent a significant source of indoor air 
pollution and have been linked to asthma, however they are more commonly associated 
with lower respiratory infections in children and chronic obstructive pulmonary disease 
(COPD) in adults74.  In atopic individuals, irritation of the respiratory tract by particulates 
can exacerbate underlying disease.  Particulates are therefore an important cause of 
clinical symptoms, and exposure to multiple inflammatory stimuli such as chemical 
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irritants and respiratory infections represent a common scenario requiring medical 
intervention or hospitalization in affected individuals75. 
 
Viral exacerbations and respiratory syncytial virus (RSV) 
The exacerbation of underlying airways disease by viral infections is a common 
cause of significant respiratory pathology in asthmatics1,76,77.  Infants and children are 
especially at risk, and several studies have linked severe and/or repeated early childhood 
viral infections to the development of allergic asthma78-81.  Upper and lower respiratory 
tract infections not only increase the likelihood of an asthmatic phenotype, they also 
worsen existing disease and represent the most common precipitant for hospitalization 
among children under two years of age82.  In 2003, viral respiratory tract infections 
accounted for approximately 1 in 5 hospital admissions in the United States among 
infants under one year old83.  Common viruses include influenza, parainfluenza, 
rhinovirus (RV), and respiratory syncytial virus (RSV)83,84.  Influenza, particularly the 
H1N1 strain, has been a source of significant morbidity and mortality among pediatric 
and adult asthmatics85,86.  The effects of H1N1 infection have also been particularly 
severe in obese individuals with underlying airway dysfunction86,87.  RV represents the 
most common viral cause of asthma exacerbations, however its clinical symptoms are 
generally less consequential than either influenza or RSV infection, in part due to 
variation in the pathogenicity of the more than 100 RV strains88,89.  The virus most 
associated with type 2 immunopathology (and the most common cause of severe 
exacerbations) is RSV79,90,91. 
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As with each of the risk factors associated with allergic asthma, the number of 
positive predictive factors an individual has alters his or her odds of developing disease.  
Early life viral infections appear to be critically important, and have multiplicative effects 
on the risk for an eventual asthma diagnosis65,92.  For example, individuals with 
sensitivities to HDM have an up to seven-fold higher risk for developing asthma if also 
they experience a severe respiratory infection with either RSV or RV65.  Genetic 
predisposition also plays an important role.  Children hospitalized with RSV bronchiolitis 
before their first birthday are at a five-fold increased risk of asthma if a parent also has a 
history of allergic disease78. 
RSV is a ubiquitous pathogen responsible for the majority of lower respiratory 
tract infections in children93.  Upwards of 95% of children have been exposed by age 
two94,95, and although subsequent infections are generally less severe, RSV represents a 
difficult target for the adaptive immune system in that T and B cell memory does not 
prevent reinfection from occurring throughout life96-98.  Opportunistic infections with 
RSV can have significant impacts on elderly and immunocompromised populations99-101, 
and present with variable symptoms ranging from asymptomatic illness to bronchiolitis 
requiring hospitalization and, in the most severe cases, death due to respiratory failure.  
Initial attempts to generate a vaccine against RSV ended in failure when individuals 
inoculated with formalin–inactivated virus became hyper-responsive to subsequent RSV 
infection, causing profound type 2 inflammation, mucus hypersecretion, and pulmonary 
eosinophilia102,103.  RSV’s clinical importance, and the absence of an effective vaccine, 
therefore makes understanding immune regulation of RSV infection an important area of 
research. 
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RSV is a single stranded RNA virus of the family Paramyxoviridae104 with a 
nonsegmented 10 gene genome105.  The attachment (G) and fusion (F) surface 
glycoproteins permit virion infection of host epithelial cells, and are the most important 
determinants of viral pathogenicity106,107.  The characteristic multinucleated epithelial 
cells, or syncytia, of RSV are the result of F protein interactions, which mediate fusion of 
the viral envelope to the cell membrane but also permit cell-to-cell fusion106,107.  RSV is 
classified according to G protein type as belonging to one of two subgroups (A or B)108-
110.  As with other respiratory viral infections, the prevalence of each subgroup varies by 
region and from season to season, with rates of viral infection and hospitalization peaking 
in mid winter111,112. 
The pathology of severe RSV infection includes significant airway epithelial 
damage, mucus hypersecretion, and increased type 2 cytokines in the lung113,114, similar 
in many ways to the pathology associated with prolonged allergic asthma.  As with 
asthma, several investigators have linked this clinically relevant pathology not with direct 
effects of the viral infection, but with consequences of the host immune response115,116.  
RSV infection can generate a mixed inflammatory response in addition to type 2 
inflammation117.  This is the result of an induction of neutrophilic Th17 inflammation in 
addition to type 1 anti-viral responses.  Therefore, the dramatic surge in pathology that 
can accompany viral infection in asthmatic patients is related to the additive effects of 





ACQUIRED IMMUNITY AND THE PATHOGENESIS OF ALLERGIC ASTHMA 
Specificity in T helper subsets 
The adaptive immune system combats pathogens (viruses, bacteria, fungi, or 
parasites) by focusing a coordinated inflammatory response on a perceived threat. T 
helper (Th) cells differentiate into discrete subtypes, characterized by production of 
specific cytokines, for effective host clearance of the pathogen.  For example, while T 
helper-type 1 (Th1) cells are specialized to battle intracellular threats, T helper-type 2 
(Th2) cells respond to parasitic infections2.  T helper-type 17 (Th17) inflammation 
represents a third arm of the adaptive immune response associated with anti-microbial 
immunity118.  The pro-inflammatory actions of these subsets are tempered by anti-
inflammatory signals from T regulatory (Treg) cells, a subset with developmental ties to 
Th17 cells119.  Each of the Th subsets can function to alter the severity of allergic airway 
disease.  The following is a concise review of Th1, Th2, and Th17 development, their 
functions in regulating immunity and inflammation, and the contribution of key cytokines 
to each subset’s function. 
Regardless of the pathogen in question, in order for a naive helper T (Th0) cell to 
become a participant in the adaptive immune response, it must be activated by an antigen 
presenting cell (APC) via stimulation with both the Th cell’s cognate antigen and one of 
the co-stimulatory B7 family proteins120.  APCs, most commonly dendritic cells (DCs), 
sample the external environment by taking up antigen, and detect pathogens with pattern 
recognition receptors (PRRs) such as the toll-like receptors (TLRs)121,122.  Pathogen 
associated molecular patterns (PAMPs) can trigger PRR activation directly on an APC, or 
can be recognized by cells of the innate immune system via TLRs, which are activated 
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upon PAMP binding and can then provide an indirect mechanism for APC 
stimulation121,122.  APCs then migrate to secondary lymphoid tissues (i.e. lymph nodes 
and spleen), where the processed antigen is presented and a T cell with a matching T cell 
receptor (TCR) is activated120.  This initiates the process that culminates in T helper cell 
polarization and the generation of an adaptive immune response. 
Following activation, T helper cells undergo clonal expansion and mature into 
effector phenotypes characterized by discrete profiles of cytokine production2,118-120.  The 
specificity of these cytokine profiles serves as the basis for classifying effector cells as 
Th1, Th2, Th17, or Treg populations.  The regulatory processes by which this occurs are 
complex.  In short, cytokine expression in the extracellular environment plays a key role 
in activating subset-specific genes, suppressing competing differentiation profiles, and 
stabilizing an established T helper phenotype.  Th1 and Th2 subsets were initially 
distinguished by their unique expression patterns of Interferon (IFN)-γ and Interleukin 
(IL)-4123.  Subsequent reports indicated important functional differences between subsets, 
related directly to cytokine secretion from these populations124.  Th1 cells respond to 
intracellular viruses and bacteria by producing IFN-γ, Tumor Necrosis Factor (TNF)-α, 
and TNF-β125.  Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 in response to 
helminth infection2, and Th17 inflammation, defined by the secretion of IL-6, IL-17A, 
IL-17F, IL-21, and IL-22, plays a critical role in inducing the inflammatory response to 
extracellular bacteria118. In contrast to their pro-inflammatory counterparts, Tregs 
function to suppress effector responses via the secretion of IL-10 and TGF-β, thereby 




 Interactions between Janus kinases and signal transducers and activators of 
transcription (JAK-STATs) are required for the vast majority of cytokine-induced 
signaling cascades in target cell populations127. T helper subtypes achieve specificity of 
function, in part, by secreting cytokines that induce the activation of distinct STATs, 
which are phosphorylated, dimerize, and translocate to the nucleus to induce additional T 
helper lineage-specific transcription factors, which function as master regulators of gene  
expression for each Th subtype (summarized in Table 1.1).  Th1 differentiation requires 
signaling via IL-12/STAT4 or IFN-γ/STAT1 for the induction of the transcription factor 
T-bet128.  Th2 differentiation uses IL-4/STAT6 for GATA-3 upregulation129, and Th17 
relies upon IL-23/STAT3 for RORγT activation and the maintenance of RORγT 
expression130.  Tregs require IL-2/STAT5 for the activation of forkhead box P3 
(Foxp3)131, however once they develop, Tregs do not require TCR activation or co-
stimulation to suppress pro-inflammatory responses126.  The utilization of unique 






















IL-12 JAK2/tyk2 STAT4 
Tbet IFNγ, TNF-β 















inflammation Treg IL-2 JAK1/JAK3 STAT5 Foxp3 IL-10 
 
Table 1.1: JAK:STAT signals required for activation of CD4+ T-helper subsets.127-133 
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allows for tight regulation of complex inflammatory processes that involve multiple cell 
types, tissue-specific responses, and temporal regulation, thereby enabling the immune 
system to effectively target invading pathogens. 
 
The allergic cascade 
Th2 lymphocytes represent critical components of type 2 inflammatory responses 
in patients with symptoms of what is known clinically as the “Atopic Triad”: asthma, 
allergic rhinitis, and atopic dermatitis134.  Non-atopic individuals maintain tolerance to 
environmental allergens because CD4+ T cells with TCRs matching allergen-specific 
epitopes are either anergic (i.e. they do not respond to TCR stimulation) or are 
Tregs135,136.  In atopic disease, when tolerance fails and an individual becomes sensitized 
to an allergen, the host utilizes a stereotyped inflammatory response to remove the 
inciting antigen.  The symptoms of asthma are the result of collateral damage incurred as 
immunologic machinery designed to expel invading helminths works to “destroy” the 
otherwise innocuous allergen1.  The type 2 cytokines IL-4, IL-5, and IL-13 are most 
closely associated with allergic asthma, and promote its pathogenesis.  Both innate and 
adaptive populations are sources of these cytokines, a topic that will be discussed at 
length in subsequent sections and throughout this thesis. 
IL-4 (formerly known as B cell stimulating factor 1 (BSF1) or B cell growth 
factor (BCGF))137 stimulates the type 2 immune response by inducing B cell 
proliferation, class switching, and the secretion of allergen-specific IgE, which binds to 
high affinity IgE receptors (FcεRI) on mast cells and basophils138,139.  Upon subsequent 
allergen exposure, allergen activates and crosslinks FcεRI on these cells and triggers a 
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pro-inflammatory cascade characterized by the release of secretory granules and the 
synthesis of pro-inflammatory compounds140.  Mast cell degranulation stimulates a 
variety of changes in the airway, including increased vascular permeability, constriction 
of the airway smooth muscle, and mucus hypersecretion from goblet cells139,141.  Secreted 
compounds include pre-formed mediators such as histamine, various proteases (tryptase, 
chymase, and carboxypeptidase), lipid mediators such as the prostaglandin PDG2 and the 
leukotriene LTC4, cytokines (including TNF-α, IL-4, and IL-13), and chemokines 
(including MCP-1 (CCL2), CCL5, and Eotaxin (CCL11))30,141.  Mast cell degranulation 
marks the early phase of the allergic response, and lasts for 3-4 hours following allergen 
exposure.  The inflammatory cytokines and chemokines released during the early phase 
allergic response induce the recruitment and activation of a variety of innate immune 
populations responsible for mediating the so called “late phase” of allergic inflammation. 
During the late phase allergic response, chemokines released during the early 
phase recruit inflammatory populations including eosinophils, macrophages and Th2 cells 
to the airway141.  Th2 cells express the chemokine receptors CCR3 and CCR4, and are 
recruited by several ligands that can interact with these receptors142.  Once at the site of 
inflammation, they produce type 2 cytokines that promote additional inflammatory 
influx.  Eosinophils are the primary granulocytic population recruited by a type 2 
inflammatory response, and represent a terminally differentiated granulocytic subset that 
causes much of the pathology associated with allergic disease139,143. 
IL-5 is essential for eosinophilic inflammation, and promotes eosinophil 
maturation, activation, and migration from the bone marrow144,145.  IL-5 provides an anti-
apoptotic, pro-survival signal to eosinophils and triggers upregulation of the chemokine 
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receptor CCR3146.  Ligands for CCR3, such as CCL2 and CCL11, recruit eosinophils to 
sites of allergic inflammation and are produced by multiple populations including mast 
cells, Th2 cells, macrophages, and airway epithelial cells in response to stimulation with 
IL-13147.  Eosinophils attack perceived pathogens with a variety of enzymes including 
major basic protein (MBP), eosinophil peroxidase (EP), and eosinophil cationic protein 
(ECP)30,148,149.  Eosinophil numbers correlate directly with the severity of asthma, 
exhibiting a linear relationship between increased eosinophil numbers in bronchoalveolar 
lavage (BAL) fluid and worsening asthma symptoms149,150.  They are also important 
contributors to chronic inflammatory disease and are involved in airway remodeling and 
fibrosis143. 
IL-13 has several effects on cells of the respiratory tract.  IL-13 induces goblet cell 
hypertrophy and mucus hypersecretion151-155, and elicits adhesion molecule expression on 
endothelial cells, enabling the recruitment of additional leukocyte populations to areas of 
inflammation153.  IL-13 is also an important mediator of airway remodeling, a critical 
consequence of chronic allergen exposure whereby the structure of the airways is 
altered153.  In individuals with allergic asthma, chronic inflammation results in smooth 
muscle hypertrophy and the deposition of excess collagen matrix, making the airway 
more bronchoconstrictive and less elastic.  IL-13 acts directly on fibroblasts to induce 
production of the pro-fibrotic cytokine transforming growth factor–β (TGF-β), which in 
turn stimulates deposition of type I collagen152,156.  It also drives alternatively activated 
macrophages (AAMs) towards a pro-fibrotic phenotype.  This process, coupled with 
excess mucus production, reduces the luminal diameter of affected bronchioles and leads 
to worsening obstructive lung disease in asthmatics.  The neutralization of IL-13 reduces 
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airway hyperreactivity (AHR), mucus hypersecretion, and the airway remodeling 
associated with chronic allergen exposure155.  Similarly IL-13-/- mice are protected from 
these pathologically important, allergen-induced sequelae, despite maintaining a 
significant amount of airway eosinophilia and high levels of IL-4 and IL-5151,155,157. 
 
 
Figure 1.1 Type 2 cytokines regulate the pathogenesis of allergic asthma. Upon 
encountering environmental allergens in the lung, APCs phagocytose, process, and 
present allergen epitopes on the cell surface.  APCs traffic to draining LNs where naive  
T cells with TCRs complimentary to the expressed epitopes are activated, differentiate 
into an effector phenotype, and traffic to the site of inflammation.  In type 2 diseases such 
as allergic asthma, activated T cells are skewed towards a Th2 response by IL-4 and the 
activation of the transcription factor GATA3, and secrete IL-4, IL-5, and IL-13.  These 
cytokines function to promote the inflammatory response characteristic of allergic asthma 
by promoting B cell class switching, the recruitment of eosinophils, and goblet cell 




While the most likely inflammatory response to an allergen is an allergic cascade 
associated with type 2 inflammation and eosinophilia, individuals with severe asthma 
(including steroid-resistant asthmatics) can exhibit a mixed inflammatory environment 
with components of Th17 or Th1 inflammation in addition to the typical Th2 
response33,34,36,158-161.  In such cases the inflammatory milieu may include a neutrophilic 
influx, driven in part by high levels of IL-17A expression160,162,163.  In contrast to 
eosinophilic infiltrates associated with IL-5 production during Th2 inflammation, 
neutrophils represent the primary granulocytic population recruited by Th17-mediated 
responses.  Neutrophil chemotaxis requires interactions between the chemokine receptors 
CXCR1 and CXCR2 (mice only express CXCR2) and one of several CXC family 
ligands, including CXCL1 and CXCL8 (also known as IL-8)147,164.  These are produced 
by airway epithelial cells (AECs) in response to IL-17A, and may represent a primary 
mechanism for the severity of some asthma patients’ symptoms165.  Activated neutrophils 
use several enzymes to produce reactive oxygen species, and neutrophil recruitment can 
cause widespread nonspecific damage to the airways164,166.  Some severe asthma patients 
also exhibit increased levels of IFN-γ, which can induce activation of both eosinophils 
and neutrophils162. 
 Allergic inflammation is typically a reversible process in which infiltrates are 
cleared in the aftermath of allergen exposure, thus allowing for a resolution of symptoms 
and a return to normal lung physiology3.  However, chronic exposure, resulting in IL-13-
mediated remodeling, makes the complete resolution of symptoms unlikely and 
predisposes an individual to future pathology, as the pulmonary environment is primed to 
respond forcefully to antigenic stimuli152.  An emerging area of research has focused on 
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the role of epithelial cell biology in mediating the pro-inflammatory processes that mark 
asthmatics as prone to allergen exacerbations.  The respiratory epithelium is a dynamic 
actor in the immune response to “non-self,” and has been increasingly recognized for its 
importance in the pathogenesis of asthma. 
 
 
COORDINATING INFLAMMATORY RESPONSES AND CYTOKINE 
PRODUCTION AT MUCOSAL SURFACES 
 
Epithelial cells: mediators of mucosal immunity 
The mucosal surfaces of the lungs and gastrointestinal (GI) tract represent critical 
areas at which cells of the innate and adaptive immune system interact to coordinate 
responses against invading pathogens167.  As the sites where APCs and other immune 
cells receive constant stimulation from innocuous environmental antigens, these epithelial 
barriers are necessary for the maintenance of a homeostatic steady state in which 
inflammatory cells respond only to those stimuli that represent legitimate threats to the 
health of the host168.  In the last decade, it has become increasingly apparent that the 
mucosal epithelium serves as more than a barrier to potential pathogens.  It is often 
“ground zero” in the initiation of an inflammatory response to invading pathogens, and 
can secrete a variety of pro-inflammatory mediators to initiate a response when 
necessary167-171.  Although these responses are tightly controlled, the disruption of normal 
epithelial function contributes to inflammatory diseases such as asthma, and represents a 
mechanism by which allergic individuals may experience flares of inflammation 
following exposure to atopic triggers.  Three epithelial-derived cytokines in particular are 
associated with antigen-independent activation of type 2 inflammatory responses.  These 
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cytokines, thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 (IL-17E), have been 
identified as promoters of innate and adaptive immune responses2,171,172.   
Briefly, each of these three epithelial cell-derived cytokines is expressed in a 
variety of tissues including the skin173, lung174, and GI tract22, and all are associated with 
type 2 inflammation.  Each signals through NFκB, however the receptors and adapter 
proteins associated with each cytokine differ greatly171,175-177.  With regards to asthma 
and atopy, all three cytokines may be produced following allergen exposure and regulate 
type 2 cytokine production on both T lymphocytes as well as cells of the innate immune 
system.  TSLP appears to play an important role in the genesis of the inflammatory 
response, primarily by activating APCs and Basophils18,178.  IL-33, an IL-1 family 
member, exhibits multiple effects on cells of the innate immune system and also appears 
to be involved in the initiation of type 2 responses175.  Like other IL-1 cytokines, IL-33 is 
secreted as an inactive precursor; however unlike IL-1 or IL-18, IL-33 requires activation 
via neutrophil elastase and cathepsin G, and is inactivated by caspase 1-mediated 
proteolytic cleavage179. The third epithelial cell-associated cytokine, IL-25, has been 
established as a regulator of type 2 inflammation and multiple reports have described its 
ability to exacerbate inflammatory responses at mucosal epithelia, including those in 







The IL-17 family 
IL-17 family cytokines have been identified as critical components in the 
induction and regulation of Th2 and Th17 inflammatory processes.  The IL-17 family 
consists of 6 homologues, classified A-F180-182.  Each IL-17 homologue has distinct tissue 
and cell-specific expression patterns and interacts with a variety of cell types; key aspects 
of IL-17 family biology are summarized in Table 1.2.  The prototypical IL-17 family 
member, IL-17A, promotes what is classically described as Th17-mediated 
pathology180,182.  The well-established link between IL-17A and autoimmunity is an area 
of active study for many investigators, however the following discussion will focus on 
IL-17A’s role as a critical component of host defense against extracellular pathogens.  IL-
17A’s pro-inflammatory effects are the result of multiple downstream cytokines, 
including GM-CSF, IL-6, IL1β, TNF-α and TGF-β180,183.  At mucosal surfaces (lung and 
gut) the Th17 response is characterized by excess mucus production and neutrophilic 
influx following the IL-17-mediated induction of the neutrophil chemokine IL-8159,183,184. 
IL-17F has similar pro-inflammatory effects, however (perhaps because its binding 
affinity is 30-40 times lower than IL-17A)176 IL-17F does not appear to drive as robust an 
inflammatory response and has been associated with asthma but not autoimmunity185. 
IL-17 family members adopt a unique conformational structure, employing a “cysteine 
knot” fold similar to members of the neurotrophin family186,187.  Like the neurotrophins, 
IL-17 members assemble as non-covalently bound homodimers182,186, which interact with 
specific receptor homo or heterodimers (although IL-17A-IL-17F heterodimers have been 
produced by human monocytes and CD4+ T cells in vitro, and exhibit an intermediate 
binding affinity compared to pure A or F isoforms)182,188,189.  IL-17 family homologs A 
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and F signal through a heterodimer of IL-17 Receptor A (IL-17RA) and IL-17RC176, 
whereas IL-17C, which has been shown to induce similar inflammatory effects in vivo, 
requires a heterodimer of IL-17RA and IL-17RE190-192.  IL-17E, also known as IL-25, 
signals through an IL-17RA/IL-17RB heterodimer193.  Table 1.2 synopsizes known 
ligand-receptor interactions among IL-17 family members, as well as the signaling 
cascades shared by IL-17A, F and IL-25194. 
 




human IL-17A Receptor 
Tissue 
distribution Effects 
      
IL-17A 62% 100% 
IL-17RA / 
IL-17RC 
Th17 cells, CD8+ T 
cells, γδT cells, NK 
cells, NKT cells, 
and LTi cells 
A, A/F: Autoimmune 
pathology  
A, A/F, F: Neutrophil 
recruitment, immunity to 
extracellular bacteria/fungi 
IL-17F 77% 55% 
IL-17A / F 
heterodimer --- --- 
Observed in 
monocytes/ Th17 
cells in vitro 
IL-17B 88% 29% IL-17RB 
Cells of the GI tract, 
pancreas, and 
neurons 
Unknown: Activates TNF-α 
and IL-1β in THP-1 cells 
IL-17D 78% 25% Unknown 
Cells of the muscles, 




expression in endothelial 
cells 






production in epithelial cells, 
mediates immunity against 
extracellular bacteria 
IL-17E /  







cells, basophils, Th2 
cells, cells of the 
uterus and GI tract 
Promotes type 2 immune 
responses to parasitic 
infection, chemical irritants, 
environmental allergens; 
suppresses type 1 and Th17 
inflammation 
 
Table 1.2: IL-17 family ligands.  Ligands are ordered according to sequence homology 
with IL-17A.  Ligands assemble as noncovalently bound homodimers and interact with 
ligand-specific receptor dimers.19,130,176,180-183,185,186,188-201 
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Unlike the JAK-STAT dependent signaling necessary for cytokine mediated 
induction of type 1 and type 2 inflammation (summarized in Table 1.1) IL-17 family 
members utilize signaling cascades more commonly associated with innate immunity. 
These signals are similar to those used by the MyD88 dependent Toll-like Receptors 
(TLRs) and IL-1 family cytokines182,186,200.  In fact, a similar binding motif sequence has 
been identified on both IL-17RA and Toll/IL-1-receptors, both of which also induce 
NFκB and P38 MAPK following receptor activation.  For example, despite their differing 
biological functions, signaling by IL-17A, F, and IL-25 each require ACT1 and TNFR-
associated factor 6 (TRAF6) for the NFκB-dependent activation of downstream target 
genes202-205.  In addition, both IL-17A and IL-25 phosphorylate P38-dependent MAPK to 
achieve cytokine-specific effects: mRNA stabilization in the case of IL-17A206, and 
Suppressor of Cytokine Signaling 3 (SOCS3) activation in the case IL-25198.  The 
downstream pathways and biological relevance of IL-17B and IL-17D have not yet been 
determined. 
Khader et al. summarized the unique effects of Th17 cells as, “a bridge between 
innate and adaptive immunity against infectious disease at the mucosa207.”  Although in 
this case the authors were referring to IL-17A and IL-17F-induced Th17 inflammation, a 
major component of this thesis involves investigations of the biological activity of IL-25.  
IL-25 shares the least structural homology with other IL-17 family members176,182,186 and 
this structural difference imparts significant differences in its biological effects as well.  
A linking of innate and adaptive type 2 immunity, mediated by IL-25-responsive 




 Unlike the Th17 inflammation and neutrophilia induced by other IL-17 family 
members, IL-25 regulates mucosal immunity by promoting a type 2 inflammatory 
response. Both exogenous administration and overexpression of IL-25 induce the 
production of IL-4, IL-5, and IL-134,5,7,10.  Investigators examining IL-25’s role in the 
mucosal biology of the small intestine have identified it as a critical mediator of type 2 
inflammation, required for clearance of the murine intestinal parasite Trichuris muris6.  
IL-25-/- mice infected with T. muris were unable to mount an effective type 2 
inflammatory response and instead exhibited an upregulation of both IFNγ and IL-17A.  
These mice could not clear the parasite, and suffered much greater disease burden as a 
result.  The same group also identified a critical role for IL-25 as a regulator of Th17 
inflammation, and determined that commensal intestinal bacteria were required for IL-25 
production by the intestinal mucosal epithelia208.  In the gut, IL-25 functions to maintain 
the normal immune environment by inhibiting excess Th17 inflammation6,208-210. 
 At the pulmonary mucosa, IL-25 induces an inflammatory pathology with many of 
the hallmarks of allergic asthma, including airway hyperreactivity, mucus hypersecretion, 
and eosinophilia4,5,7,15,193.  Pulmonary sources of IL-25 include eosinophils11,14, mast 
cells12, alveolar macrophages13, and the airway epithelium itself7.  Like other type 2-
associated cytokines, IL-25 is produced by the respiratory epithelium in response to 
noxious stimuli2, including environmental allergens, especially those with protease 
activity66,211,212.  One report also indicates that it may be induced by viral respiratory 
infection213. 
 The induction of IL-25-mediated responses requires binding of a noncovalently 
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bound IL-25 homodimer to the IL-17RA/IL-17RB heterodimer176,182,186,193 (Figure 1.2), 
of which IL-17RB represents an IL-25 specific moiety in the lung195.  IL-25 is known to 
enhance Th2 effector functions via Act1 and TRAF6 dependent NFκB 
activation18,203,205,214. Multiple cell types present in the lung, including memory18 and  
 
 
Figure 1.2: Signaling cascades induced by IL-25-IL-25 receptor interaction.  IL-25 
promotes type 2 cytokine production and an asthma-like inflammatory response. The cell 
types listed reflect those cells in which aspects of IL-25 signaling were first identified. 
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effector18,215 T cells, invariant NKT cells19,216, APCs17, and airway smooth muscle217, 
have been characterized as expressing IL-17RB.  The effects mediated by IL-25 in these 
populations differ, and to date, data regarding IL-25’s role in atopic asthma are by no 
means definitive10,11,15,16,18,201,209,218.  Several recent studies have also identified additional 
IL-25 responsive, type 2 cytokine producing, innate lymphoid populations20-23 which will 
be discussed shortly. 
 Since its identification in 2001195, IL-25’s role as an inducer of type 2 inflammation 
has been investigated in a variety of clinical contexts.  IL-25 and IL-17RB expression are 
increased in skin biopsies from patients with Atopic Dermatitis219,220.  Autoimmune 
hypereosinophilia, (also known as Churg-Strauss syndrome) is a small to medium vessel 
vasculitis associated with asthma and eosinophilia.  Biopsies of CS patients identified IL-
25 production in eosinophils, and lymphocyte populations at lesion sites demonstrated 
almost ubiquitous expression of IL-17RB, suggesting the importance of IL-25-associated 
inflammation in mediating aspects of the disease14.  With regard to pulmonary pathology, 
a recent clinical study found that allergen provocation increases IL-25 and IL-17RB 
expression in peripheral blood mononuclear cells (PBMCs) from patients with seasonal 
allergic rhinitis221.  A separate study compared lung biopsies from atopic individuals 
before and after allergen challenge, and correlated the allergen-induced expression of IL-
25/IL-17RB in atopic asthmatics with severity of disease symptoms222.  Lastly, there is 
genetic evidence for the importance of both IL-17RB and IL-25 in human disease.  
Polymorphisms in IL-17RB have been associated with an increased risk for severe 
asthma223, and investigators have also published a case report describing a primary 
immunodeficiency associated with IL-25 overexpression224.  In the affected individual, 
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the overexpression of IL-25 polarized the immune system towards type 2 inflammation, 
making the patient prone to pathogens requiring a type 1 immune response for clearance.  
Taken together, these data demonstrate the importance of IL-25 in the normal functioning 
of type 2 immune responses. 
Initial experiments to determine the cellular targets of IL-25 produced a 
somewhat starling discovery.  IL-25 induced type 2 inflammation, and although cytokine 
production in Th2 effector and memory cells was undoubtedly increased by IL-25, the 
exogenous administration of IL-25 into Rag2-/- mice (which lack both T and B cells) still 
induced type 2 cytokine production and recapitulated type 2 mediated pathology4.  These 
findings were the first to suggest the existence of an IL-25 responsive non-T cell, non-B 
cell (NBNT) population as a source of type 2 cytokines.  Since this discovery several 
groups have sought to identify what had been characterized initially as a NBNT myeloid 
source of type 2 cytokines. 
 
Innate sources of type 2 cytokines 
 Th2 development requires IL-4 to polarize Th0 cells towards a Th2 phenotype.  
While the adaptive immune response ultimately contributes IL-4 and IL-13 (two 
cytokines required for parasite expulsion) the innate immune system is responsible for 
type 2 cytokine production in the initial stages of infection.  A 2004 study by Voehringer 
et al. described NBNT IL-4 producing populations induced by infection with the hook 
worm–like parasite Nippostrongylous brasiliensis, and described eosinophils, basophils, 
and mast cells as innate sources of IL-4225.  In a follow-up study, the same investigators 
reported that type 2 cytokines from eosinophils were not required for Th2 cell 
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development, but were critically important for the maintenance of type 2 immune 
responses226.  As further evidence of the critical importance of bone marrow derived 
innate populations, it was shown that innate IL-4/IL-13 production was required for N. 
brasiliensis expulsion, while Th2-derived IL-4/IL-13 was not necessary for effective 
parasite clearance.  In 2009, three groups reported that basophils were key to the 
development of type 2 immunity in the gut, functioning as IL-4 producing APCs with the 
capacity to migrate to draining lymph nodes, thereby rendering them both necessary and 
sufficient for the induction of adaptive immune responses and polarization to Th2227-229.  
Subsequent investigations, however, have questioned the role of basophils in the 
pathogenesis of allergic asthma230,231.  These include the finding that certain 
inflammatory DC subsets express the high affinity IgE receptor I (FcεRI), the same cell 
surface mark used for both discrimination and depletion of basophil populations in the 
previous studies, and that it is these FcεRI+ DCs, not basophils, that are required for Th2 
polarization232.  What is not in dispute is the critical importance of innate type 2 cytokine 
production in inflammatory responses.  While these investigations shed light on innate 
cytokine producing populations, they do not address the role of IL-25 as a mediator of 
type 2 responses. 
Our lab sought to further explore the connection between IL-25 and innate 
cytokine producing cells, as published in 200911.  We identified a non-eosinophilic, non-
basophilic, IL-4 producing myeloid population that was recruited to the airway in the 
context of repeated allergen exposure.  This population expressed IL-17RB and was stem 
cell factor (SCF) dependent, indicating that it required activation of the receptor tyrosine 
kinase c-kit to promote activation, differentiation, or both in order for the cell to be 
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recruited from the bone marrow.  These results merited further investigation into the 
biology of IL-25-reponsive myeloid populations, and this thesis is the product of those 
pursuits.  Recent findings have identified additional, previously unrecognized sources of 
type 2 cytokines at mucosal sites in both the lung and GI tract that are IL-25 and IL-33 
responsive and associated with mucosal inflammation. 
Innate IL-25/IL-33 responsive type 2 cytokine producing populations have been 
reported by four groups, and have been named Multipotent progenitor type 2 (MPPtype2) 
22 cells, Nuocytes21, Innate type 2 helper (Ih2) cells23, and Natural helper cells (NHCs)20, 
respectively.  These innate lymphoid populations share a common lymphoid morphology 
and distinct cell surface receptor expression.  All four populations lack mature Lineage 
markers (CD4, CD8, CD45R (B220), CD11b, Gr-1 (Ly6C/G), and Terr-119), and so by 
definition are not T cells, B cells, monocyte-macrophages, granulocytes, or erythrocytes, 
and are c-kit+ and Sca1+.  MPPtype2, Nuocytes, and Ih2 cells are present in spleen and 
mesenteric lymph nodes (mLN), are important components of type 2 immunity in 
response to helminth infection, and function to mediate helminth expulsion via the 
production of IL-5 and IL-13.  NHCs are found in structures known as Fat-associated 
lymphoid clusters (FALC), and although they produce IL-5 and IL-13, their role in type 2 
immunity remains undefined.  Each research group identified functional or phenotypic 
differences between these cell types, including differences in cell surface receptor 
expression, transcription factor expression, and degree of responsiveness to IL-25 and/or 
IL-33.  Questions remain as to whether these populations are in fact the same cells 
characterized in slightly different inflammatory contexts, or whether each represents a 
discrete population, although it seems likely that these cells share a common 
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progenitor233.  The most pronounced difference with regard to innate lymphoid 
populations involves their plasticity.  Whereas Nuocytes, Ih2, and NHCs appear to be 
terminally differentiated20,23,234, MPPtype2 cells can give rise to macrophages, basophils, 
and mast cells22. 
 The identification of innate lymphoid cells has sparked a great deal of interest 
among researchers focused on type 2 inflammation and mucosal immunology. One of the 
investigative groups credited with the discovery of innate lymphoid cells has 
subsequently described nuocytes in the context of allergic airways disease235, indicating 
that these cells may play a role in type 2 immunity at multiple mucosal sites.  Innate 
lymphoid cells, similar to nuocytes and Ih2 cells, were also identified as playing a 
significant role in the resolution (not exacerbation) of inflammation following influenza 
A infection, specifically via upregulation of the epidermal growth factor receptor (EGFR) 
amphiregulin236.  Amphiregulin production by this population played a protective role 
during influenza infection.  This is an interesting finding, as it indicates that innate 
lymphoid populations can exhibit both pro– and anti–inflammatory functions depending 
on immunologic context.  Their pro–inflammatory potential was further reinforced by the 
identification of IL-13 and IL-22 producing, IL-25/IL-33 responsive innate lymphoid 
cells in humans237.  These cells were enriched in chronic rhinosinusitus polyps (a type 2 
inflammatory condition) and characterized as Lin- CD161+ CRTH2+. 
Innate lymphoid populations represent an intriguing component of the innate 
immune system, and appear to provide an important source of type 2 cytokines produced 
in the interval between the induction of inflammation and the establishment of Th2 
immunity.  Despite convincing data of the importance of these populations in the 
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clearance of helminth infection, as well as additional reports identifying these cells in the 
lung, the relevance of innate cytokine producing populations in allergic asthma requires 
further investigation.  For example, each of these innate lymphoid populations has been 
shown to be effective producers of IL-5 and IL-13, however no studies to date have 




A primary goal of this dissertation has been to further investigate type 2 
inflammation in the context of allergic airways disease and viral infection.  The 
relationship between IL-25, innate cytokine producing cells, and the pathogenesis of 
allergic asthma forms the basis of this thesis.  The initial hypothesis for this work was 
that an IL-25-responsive myeloid population contributed to type 2 immunopathology in 
the lung.  This was based in large part on previous findings that bone marrow-derived 
type 2 cytokine producing populations were important contributors to type 2 
inflammatory responses.  Through a series of animal models, genetic manipulations, 
adoptive transfers, and a comprehensive characterization of IL-25-responsive myeloid 
populations, the studies presented in this thesis have identified a novel granulocytic 
population of innate IL-25 responsive cells involved in the pathogenesis of allergic 
asthma.  This population, termed Type 2 Myeloid (T2M) cells, produces IL-4 and IL-13, 
is recruited in large numbers to the lung in response to IL-25 secretion, and induces IL-
25-associated immunopathology in the airway.  Our findings also indicate that T2M cells 
may be of significant clinical importance.  High dose dexamethasone administration, the 
front line therapy for severe allergic asthma exacerbations, did not reduce cytokine 
 33 
production in, or total numbers of, T2M cells.  Finally, a clinical study using peripheral 
blood drawn from atopic asthmatic volunteers identified a similar IL-4 and IL-13 
producing granulocytic population.  The identification of a novel, pathologically relevant, 
granulocytic subset offers an important new avenue of research investigation with the 




Materials and Methods 
 
 
Animals and allergen model: 
Female C57BL/6J, BALBc, 4get, and Rag2–/– mice were purchased from The 
Jackson Laboratory.  Il17rb–/– mice were provided by A.L. Budelsky (Amgen).  All mice 
were used at 6–8 wk of age.  For allergen sensitization, we used clinical skin test grade, 
low endotoxin contamination (<20 ng/ml) cockroach allergen (CRA) (HollisterStier 
Laboratories).  Our chronic model was performed as previously described11,238.  Animals 
were immunized systemically (day 0) via intra-peritoneal and subcutaneous injections of 
allergen emulsified with Incomplete Freund’s Adjuvant (IFA).  After 14 days, mice were 
given 4 intranasal allergen challenges (1.5 µg in 15 µl PBS on days 14, 18, 22, and 26), 
followed by two intra-tracheal (IT) administrations (5 µg in 50 µl PBS on days 30 and 
32), for a total of 6 pulmonary allergen exposures.  Tissues were analyzed 24 hours post 
final allergen challenge.  The left lung was used for histologic analysis, upper right lobe 
for RNA analysis, middle right lobe for protein quantification, and lower right lobe for 
flow cytometric analysis.  All animal experiments were reviewed and approved by the 




Figure 2.1: Protocol for allergen-induced model of allergic airways disease. 
 
Intra-tracheal IL-25 administration and dexamethasone treatments: 
6–8 week old female C57BL/6J, BALBc, 4get, or Il17rb–/– mice received daily 
intra-tracheal injections (0.5 µg recombinant IL-25 (R&D) in 50 µL PBS) for 4 days193.  
Dexamethasone (Sigma) was administered in 2 doses (3 mg per kg per day) via IP 
injection, 1 hour prior the first and third IL-25 injections.  Tissues were analyzed 24 
hours after final IL-25 administration. 
 
Respiratory Syncytial Virus: 
Our laboratory utilized two clinical isolates of the antigenic subgroup A strain of 
RSV, referred to as Line 19239 and A2-20240, respectively.  Both have been demonstrated 
in animal models to mimic human infection by stimulating mucus production, promoting 
airway hyperreactivity, and increasing IL-13 production113,240.  Line 19 virus was used for 
experiments in BALBc mice, the A2-20 strain was used for all experiments with 
C57BL/6J mice, including Il17rb–/– animals.  All mice were infected with 5x104 PFU of 
RSV per mouse via IT injection.   
 
Antibody Administration: 
Neutralization of IL-25 was conducted using a polyclonal rabbit anti-mouse IL-25 
antibody developed in our laboratory.  Protein A column (Pierce) purified anti-IL-25 or 
 36 
control IgG was administered IP (200 µg/mouse) every other day, starting at the time of 
RSV inoculation.  Animals received five total doses of antibody, on days 0, 2, 4, 6, and 8 
post infection. 
 
Viral Exacerbation Model: 
 To simulate the effects of RSV infection in the context of allergic airways disease, 
C57BL/6J and Il-17rb–/– mice were sensitized to allergen, and then inoculated with RSV.  
Mice received 3 total allergen challenges, 2 of which occurred post RSV inoculation, and 
the inflammatory response was assessed on day 6 of RSV infection, as depicted in Figure 
2.2. 
     
Figure 2.2 Protocol for RSV-induced exacerbation of allergic airways disease. 
 
Measurement of airway hyperreactivity: 
Airway hyperreactivity was measured using mouse plethysmography, which is 
specifically designed for the low tidal volumes (Buxco Research Systems), as previously 
described.  Briefly, the mouse to be tested was anesthetized with sodium pentobarbital 
and intubated via cannulation of the trachea with an 18-gauge metal tube.  The intubated 
mice were ventilated at a volume of 200 µl at a rate of 120 breaths/min.  Airway 
resistance was measured in the closed plethysmograph by directly assessing tracheal 
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pressure and comparing the level to corresponding box pressure changes.  These values 
were monitored and immediately transformed into resistance measurements using 
computer-assisted calculations.  Once baseline levels had stabilized and initial readings 
were taken, a methacholine challenge was given via the cannulated tail vein.  After 
determining a dose-response curve (0.001–0.5 mg), an optimal dose was chosen (0.250 
mg of methacholine).  This dose was used throughout the rest of the experiments in these 
studies.  After the methacholine challenge, the response was monitored and the peak 
airway resistance was recorded as a measure of airway hyperreactivity. 
 
Lung histology: 
Mouse lungs were perfused with 10% formalin (Sigma-Aldrich) instilled directly 
into the trachea and then immersed in 10% formalin solution overnight at RT.  Serial 6 
µM sections were obtained from paraffin embedded, formalin-fixed left lungs stained 
with hematoxylin and eosin (H+E) or periodic acid-Schiff (PAS). 
 
Primary cell isolation: 
Lung tissue was processed via enzymatic digestion with 1 mg/ml collagenase A 
(Roche) in RPMI 1640 (Invitrogen) with 5% FCS (Atlas Biologicals) and 2 U DNase 
(Sigma-Aldrich) at 37°C for 1 hour then dispersed to a single-cell population by flushing 
through an 18-gauge cannula.  Draining mediastinal lymph nodes (LN) and spleen cells 
were dispersed by mechanical disruption of the LN or splenic capsule, followed by 
washing through a 40 µM filter.  Bone marrow was isolated by flushing femurs and tibias 
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Draining mediastinal lymph nodes from allergen-sensitized mice were isolated, 
and single cell suspensions were obtained as described above for in vitro experiments.  
LN cells (4x105 per well, plated in triplicate) were re-stimulated with 10 µL mL-1 
allergen, 10 ng mL-1 IL-25, or both.  RNA was isolated after 2 hours in culture; 
supernatants were analyzed for protein production after 48 hours in culture. 
 
Isolation and co-culture of dendritic cells and T cells: 
  Antigen presenting cells were isolated by culturing a single cell suspension of 
whole bone marrow from Naïve C57BL6 or Il17rb–/– mice in T150 flasks with complete 
media (10 % FCS, 1% Penicillin/Streptomycin, 1% glutamate (Invitrogen), 1% Na 
Pyruvate (Invitrogen), 1% Non-essential amino acids (Invitrogen), 50 µM β-
mercaptoethanol) and 20 ng mL–1 murine GM-CSF (R&D) at 10% CO2, 37º C for 10 
days.  Media and GM-CSF were changed every other day, cells passaged at 70% 
confluency.  CD4+ T cells were isolated from spleens of Naïve or chronically allergen 
challenged C57BL6 or Il17rb–/– mice using MACS CD4 negative magnetic selection kit 
(Miltenyl Biotech). 
Co-culture experiments were performed in 96 well plates with complete media. 
2x104 C57BL6 or Il17rb–/– DCs per well were pulsed with 10 uL mL–1 CRA for 4 hours, 
after which cells were washed and 2x105 C57BL6 or Il17rb–/– CD4+ T cells added.  RNA 
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was isolated using TRIzol (Invitrogen) after 2 hours in culture, culture supernatants were 
analyzed for protein production by Bioplex (Applied Biosystems) after 48 hours in 
culture. 
 
CD4+ T cell adoptive transfer: 
  6x106 CD4+ T cells from allergen sensitized C57BL6 or Il17rb–/– mice, isolated 
as described above, were suspended in 100 µL PBS and injected into the tail veins of 
Rag–/– recipients.  Recipient mice received 2 intra-tracheal challenges of allergen, the first 
immediately after T cell transfer and the second 4 days later.  Lungs were harvested 24 
hours after the second allergen challenge, and analyzed with the same methodology used 
in chronic allergen experiments.  
 
mRNA and Protein Quantification: 
RNA was isolated from the upper right lobes of lung, lymph nodes, and bone 
marrow using TRIzol (Invitrogen).   RNA from cells sorted by FACS analysis was 
isolated with a microprep kit (Qiagen), DNase treated (Invitrogen), and reverse 
transcribed with Superscript III (Invitrogen).  Levels of mRNA were assessed using 
quantitative PCR analysis (TaqMan) with predeveloped primers and probe sets from 
Applied Biosystems. Quantification of genes of interest was normalized to GAPDH, 
expressed as fold increases over the negative control. Protein levels of cytokines were 





Analyses of pulmonary and bone marrow cell populations were assessed using 
standard techniques.  Samples for intracellular staining were treated with 0.5 µL/mL 
brefeldin A, 0.5 µL/mL monensin, 0.5 ng/mL PMA, and 500 ng/mL ionomycin and 
incubated for 6 hours at 37ºC, 5% CO2.  Cells were stained according to manufacturer’s 
instructions (BD Biosciences Fix/Perm Kit).  Data were collected on a BD Biosciences 
LSR II flow cytometer and on a BD Biosciences FACS Aria, and analyzed using FlowJo 
software (Tree Star). The cellular surface markers of spleen cell controls were not altered 
by the collagenase treatment as compared to untreated cells consistent with our previous 
published studies.  The following monoclonal antibodies were obtained for mouse flow 















Antibody Conjugate Company Catalogue # Dilution 
     CD11b PerCP-Cy5.5 BD Biosciences 101228 1/400 
CD11c PE BD Biosciences 553802 1/400 
CD125 PE BD Biosciences 558488 1/600 
CD4 FITC BD Biosciences 553055 1/400 
CD80 PE BD Biosciences 553769 1/400 
CD86 PE BD Biosciences 553692 1/400 
CD8a FITC BD Biosciences 553031 1/400 
IL-4 AF488 BD Biosciences 557728 1/100 
IL-4 PE BD Biosciences 554435 1/100 
Ly-6G PeCy7 BD Biosciences 560601 1/400 
Nk1.1 PE BD Biosciences 553165 1/400 
     B220 PE Biolegend 553380 1/400 
c-kit PE Biolegend 105808 1/400 
CCR3 AF647 Biolegend 129401 1/200 
CD3 PeCy7 Biolegend 100220 1/400 
CD3 Pacific Blue Biolegend 100214 1/400 
CD8a PE Biolegend 100707 1/400 
Gr-1 AF700 Biolegend 108422 1/400 
IL-7ra Biotin Biolegend 121104 1/500 
Ly-6C PE Biolegend 128008 1/400 
Sca1 PeCy7 Biolegend 108114 1/600 
Streptavidin APC-Cy7 Biolegend 405208 1/200 
     c-kit APC eBioscience 17-1171-82 1/400 
CD11c eFluor780 eBioscience 47-0114-82 1/400 
CD4 PeCy7 eBioscience 25-0041-82 1/400 
CD49b PE eBioscience 12-5971-81 1/400 
CD69 PE eBioscience 12-0691-83 1/400 
F4/80 PE eBioscience 12-4801-82 1/200 
FcγR1 PE eBioscience 101308 1/200 
FcεR1a AF647 eBioscience 51-5898-80 1/400 
Gr-1 eFluor450 eBioscience 48-5931-82 1/400 
IL-13 AF647 eBioscience 51-7133-80 1/100 
MHC II APC eBioscience 17-5321-82 1/1000 
     CXCR2 PE R&D FAB2164P 1/100 
ST2 PE R&D FAB10041P 1/100 




Table 2.1: Antibodies for mouse flow cytometry and T2M cell characterization. 
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Isolation of T2M Cells for Adoptive Transfer: 
CD11b+ Gr-1mid FcγR+ CD4- CD8- B220- IL-7Rα- Sca1- c-kit- cells were isolated 
by FACS from the lungs of wild type C57BL6 mice treated with intra-tracheal IL-25, as 
described above.  Isolated cells (2.0x105 per recipient) were adoptively transferred into 
the airways of IL-17RB-/- mice via intra-tracheal injection of PBS with 0.5 µg 
recombinant IL-25.  Mice received four total transfers, each at 24 hour intervals; IL-25 
alone, T2M cells alone, or T2M cells and IL-25. Lung tissue was harvested 24 hours after 
the final adoptive transfer and processed for histological and biochemical analysis. 
 
 
Figure 2.3: Gating strategy for the isolation of T2M cells.  We did not use IL-17RB as 
a marker to enrich for T2M cells used in adoptive transfers because this mouse anti-
mouse monoclonal was originally developed as a blocking antibody and we wanted to 
assess the affect of IL-25 administration on these cells.  Type 2 cytokine producing cells 
were initially characterized by their level of Gr-1 expression (see Fig 3.2c), therefore this 
marker was used to enrich for IL-17RB+ IL-25-responsive cells.  Cells isolated were 









Cells from IL-25 treated 4get mice (n = 4 mice per sample) were pooled and 
sorted by FACS, and RNA was isolated for microarray analysis. Affymetrix Mouse 430 
2.0 microarrays were processed in the University of Michigan DNA Sequencing Core 
using the WT-Pico V.2 kit. 
 
 
Figure 2.4: Gating strategy for microarray analyses. T2M Cells (IL-4/GFP+ IL-5rα- 
F4/80+ MHCIIlo CD11b+ Gr-1mid), Neutrophils (IL-4/GFP- IL-5rα- F4/80- MHCIIlo 
CD11b+ Gr-1+), Macrophages (IL-4/GFP- IL-5rα- F4/80+ MHCII+ CD11b+ Gr-1-), and 
Eosinophils (IL-4/GFP- IL-5rα+ F4/80- MHCIIlo CD11b+ Gr-1hi) were isolated for 
microarray analysis from the lungs of 4Get mice challenged with intra-tracheal IL-25.  




 All human studies were performed in accordance with an approved University of 
Michigan IRB protocol after legal consent from adult volunteers.  All subjects were 
recruited from the U of Michigan Asthma Clinic and had a physician diagnosis of asthma 
based on a clinical picture and pulmonary testing consistent with the 2007 NIH/NAEPP 
guidelines. All patients (n = 9) were persistent asthmatics and were on daily controller 
medication.  Healthy control subjects (n = 8) had not previously been diagnosed with 
asthma. 
 
Flow cytometric analysis of human peripheral blood: 
Granulocytes and PBMCs were isolated from heparinized peripheral blood (20 
ml) following separation by Ficoll-Paque (GE Healthcare).  PBMCs were isolated as per 
manufacturer’s instructions; granulocytes were isolated from the erythrocyte layer 
following erythrocyte sedimentation with 5% dextran (Sigma) at room temperature for 
30’, followed by RBC lysis with 0.2% NaCl.  For in vitro restimulation and intracellular 
cytokine staining, samples were treated with 0.5 µL mL–1 brefeldin A, 0.5 µL mL–1 
monensin, and cultured for 2 h in RPMI 1640 ± 50 ng mL–1 recombinant IL-25 (R&D).  
Cell subsets were analyzed using specific antibodies for flow cytometry using standard 
techniques.  The following monoclonal antibodies were obtained for human flow 






Antibody Conjugate Company Catalogue # Dilution 
     CD11b Pacific Blue Biolegend 301315 1/200 
CD14 AF700 Biolegend 325614 1/200 
CD177 FITC Biolegend 315803 1/200 
CD33 PerCP Cy5.5 Biolegend 303414 1/200 
CD56 (NCAM) AF700 Biolegend 318315 1/200 
IL-13 APC Biolegend 501907 3/100 
IL-4 PeCy7 Biolegend 500824 2/100 
     CD117 (c-Kit) PerCP Cy5.5 eBioscience 46-1178-41 1/200 
CD4 PerCP Cy5.5 eBioscience 45-0048-42 1/150 
CD45R AF488 eBioscience 53-0452-80 1/100 
CD8 AF700 eBioscience 56-0086-41 1/200 
HLA-DR APC efluor 780 eBioscience 47-9956-42 1/400 
     IL-17RB PE R&D FAB1207P 1/100 
 
Table 2.2: Antibodies for human flow cytometry. 
 
Statistical analysis: 
Data were evaluated by one-way ANOVA and, where appropriate, further 
evaluated with the parametric Student-Newman-Keuls test for multiple comparisons or 
the nonparametric Mann-Whitney rank-sum test.  For microarray analysis, expression 
values for each gene were assessed using a robust multi-array average (RMA).  The 
Affymetrix package of bio-conductor implemented in the R statistical language was used 




Type 2 Inflammation in Allergic Asthma is Exacerbated by the 




The pathogenesis of allergic asthma involves the induction of type 2 inflammation 
via IL-4, IL-5, and IL-13, cytokines whose production is increased by IL-25.  We utilized 
a model of CRA induced allergic asthma to identify IL-25–responsive immune 
populations following allergen challenge.  Our findings indicate that type 2 inflammation 
in allergic asthma, including the expression of Il25 and Il17rb, is a dose–dependent 
phenomenon.  The majority of IL-17RB+ cells in our model are of myeloid origin, and 
are capable of producing levels of IL-4 and IL-13 similar to those observed in activated 
CD4+ T lymphocytes.  Furthermore, the production of pro–inflammatory cytokines in 
both myeloid and lymphoid subsets is dependent, at least in part, on IL-25–IL-17RB 
interactions.  Il17rb–/– mice are protected from allergen–induced inflammation, and 
adoptive transfer experiments indicate that the type 2 response in Il17rb–/– CD4+ T cells is 
blunted compared to their WT counterparts.  Additionally, the production of type 2 
cytokine is almost entirely abrogated in Il17rb–/– myeloid cells.  These finding represent 
the first report of the inflammatory response to allergen in Il17rb–/– animals.  They 
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demonstrate the importance of IL-25 in chronic allergic inflammation, and indicate 
contributions of both classical Th2 driven inflammation, as well as IL-17RB+ myeloid 




 The inflammatory response in allergic asthma is a dynamic process, in which a 
heterogeneous population of immune cells, with functions dependent upon both 
frequency and duration of pro–inflammatory chemical queues, is recruited to the airway 
following allergen exposure3,30.  IL-25 inhibits type 19,198 and Th176,201 and promotes 
type 2 inflammatory responses at the pulmonary mucosa4-7,10,15,16,18,241,242, thereby 
enhancing the inflammatory response in allergic airways disease.  The aim of this study 
was to characterize the role of IL-25 responsive cells in the pathophysiology of allergic 
asthma, in order to determine those inflammatory subsets involved in IL-25-mediated 
pathology. 
Recent studies have emphasized the importance of IL-25 as a mediator of type 2 
responses, and marked it as a critical component in the clearance of intestinal 
helminthes6,241.  Investigators have reported on the sufficiency of IL-25 to induce marked 
type 2 responses in the lung, and both transgenic models as well as exogenous IL-25 
administration induce inflammatory responses similar to those observed in the context of 
allergic airways disease4,7,15,193.  However, no studies to date have addressed how the 
pathophysiology of IL-25-associated inflammation, or cytokine production in IL-25 
responsive populations, is affected by the loss of IL-17RB.  To that end, we examined 
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allergen-induced inflammatory responses in WT and Il17rb–/– mice.  Our investigation 
focused on systemic, allergen–mediated pathology, as well as on cell–specific effects 
related to the absence of IL-17RB.  Our lab has previously reported that type 2 cytokine 
producing myeloid cells are induced following chronic allergen exposure, and that these 
cells express IL-17RB11.  Other recent studies have stressed the importance of innate, IL-
25 responsive lymphoid populations as mediators of type 2 inflammation233.  Given these 
findings, we investigated IL-17RB+ populations and focused on the effects the loss of IL-
17RB had on these subsets. 
 
Results 
Allergen exposure induces dose-dependent type 2 inflammation and upregulates 
Il25/Il17rb 
 
Several reports have linked IL-25 expression to the severity of allergic 
asthma7,10,11,15,16.  We employed a well–established murine model of allergen–induced 
type 2 inflammation to recapitulate the pathology of allergic airways disease238, and 
assessed pathologically relevant responses following allergen exposure.  The pulmonary 
instillation of allergen promoted both airway inflammation and the induction of type 2 
cytokine expression (Fig. 3.1), and was accompanied by increased mRNA expression of 
Il25 and Il17rb (Fig. 3.1c).  Increased cytokine transcripts tracked with disease severity 
(as depicted by histology) (Fig. 3.1a) in a dose–dependent manner. Neither Ifng, other 
IL-17 family members, Il33, nor its receptor Il1rl1 were upregulated with our model of 
cockroach allergen challenge (Fig. 3.1b,c), indicating that type 2 inflammation represents 
the dominant response induced by this model. 
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Figure 3.1: Allergen exposure promotes dose-dependent type 2 inflammation.  
C57BL6 mice (n = 3 per group) were sensitized by intraperitoneal and subcutaneous 
injection of allergen in IFA, and an allergic response was localized to the lung by a series 
of 6 allergen challenges. (a) Time course of representative Periodic Acid Schiff (PAS) 
staining, taken 6 h post indicated allergen challenge.  Scale bar for left column, 400 µm; 
right column, 100 µm.  (b) Time course of pulmonary IL-4, IL-5, IL-13, IFN-γ and IL-
17A mRNA expression 6 h post allergen challenge, analyzed by QPCR.   Data represent 
the mean ± s.e.m. for each time point versus naive control. (*P < 8.44E-05, #P = 0.0008, 
+P = 0.001). (c) Time course of allergen induced IL-25, IL-17RB, IL-33, IL-17B, and 
IL17D mRNA expression 6 h post indicated allergen challenge. ST2 and IL-22 
transcripts were not detectable.  Data represent the mean ± s.e.m. for each time point 
versus naive control (*P < 0.007). 
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Allergic airways inflammation promotes recruitment of IL-17RB+ type 2 cytokine 
producing myeloid cells 
 
We have previously identified a pathologically relevant population of IL-17RB+ 
myeloid cells with the capacity to produce IL-4 during chronic allergic airway disease11.  
Our data clearly demonstrate that type 2 cytokine production following repeated allergen 
exposure is associated with increased IL-17RB transcripts, however the composition of 
IL-17RB+ inflammatory cells within this inflammatory milieu has not been previously 
characterized.  An analysis of type 2 cytokine production in IL-17RB+ inflammatory 
subsets determined that while CD4+ T cells are present following antigen sensitization, 
the most numerous IL-17RB+ IL-4 and IL-13 producing population in the lung are 
CD11b+ myeloid cells (Fig. 3.2a-c). Because IL-25 responsive innate lymphoid 
populations have been identified as important contributors to type 2 inflammatory 
responses, we examined the capacity of innate Lin- c-kit+ Sca1+ IL-17RB+ NBNT cells to 
produce type 2 cytokines.  Lin- c-kit+ Sca1+ IL-17RB+ cells comprised a relatively rare 
population in the lungs of both naive and allergen-challenged mice (range 250-1000 per 
lobe), and were not significantly increased following allergen sensitization (Fig. 3.2a,b).  
Few myeloid IL-4 and IL-13 producing cells naive were present in the lungs of naive 
mice, and the IL-17RB+ cells preferentially produced type 2 cytokine.  Myeloid IL-
17RB+ cells represented the major NBNT IL-4 and IL-13 cytokine producing population 
in the lung, producing comparable amounts of IL-13 and outnumbering cytokine 







Figure 3.2: Allergen exposure recruits bone marrow-derived IL-17RB+ IL-4 and IL-
13 producing myeloid cells to the lung.  (a and b) IL-17RB+ lung subsets from naive 
and allergen sensitized C57BL/6J mice (n = 5 per group) were assessed by flow 
cytometry for IL-4 and IL-13 production. (c) Representative flow plots of intracellular 
cytokine staining in IL-17RB+ CD11b+ Gr-1mid cells from naive and allergen sensitized 
C57BL/6J mice.  Gray: n-1 staining, black: naive IL-17RB+ CD11b+ Gr-1mid, red: 




Figure 3.3: Comparison of IL-13 production in CD4+ T cells versus myeloid cells.  
WT C57BL/6J mice were sensitized to allergen and pulmonary populations were 
assessed by flow cytometry.  Myeloid cells were identified by gating on the CD11b+ 
Gr1mid IL-17RB+ population (as in Fig. 3.2c), and IL-13 production was assessed in both 
myeloid and CD4+ T cells.  (a) Representative dot plots of pulmonary IL-13 staining for 
CD4+ T cells and myeloid cells. Analysis of IL-13 production in CD4+ T cells versus 
myeloid cells demonstrates a higher percentage of IL-13+ cells among the myeloid 
population.  Histograms were derived from total CD4+ or myeloid populations, 
respectively.  For histograms: gray shaded area: isotype, black line: cells from naive 
animals, red line; cells from allergen sensitized animals, blue line: IL-13+ CD4+ T cells, 
shown to illustrate the relative intensity of positive IL-13 staining. Data are representative 
of 2 independent experiments (n = 5 mice per group). (b) Mean fluorescence intensity 
(MFI) of IL-13 staining in pulmonary derived cells.  The MFI of total Myeloid (CD11b+ 
Gr-1mid IL-17RB+) cells, total CD4+ T cells and the IL-13+ subsets of these populations 
was assessed.  (c) Total number of cells per lobe in allergen sensitized mice.  While 
average IL-13 production was higher in CD4+ T cells (panel b), following allergen 
challenges there were, on average, 68.5 IL-13+ myeloid cells for each IL-13+ CD4+ T 
cell. Bars represent the mean ± s.e.m. of values recorded from 5 mice, data are 
representative of 2 independent experiments. 
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 Despite significant increases in IL-4 and IL-13 producing myeloid cells in 
environments with elevated levels of IL-25, not all pulmonary IL-17RB+ myeloid 
populations appeared to produce these cytokines.  Analysis of IL-4 and IL-13 production 
in IL-17RB+ myeloid subsets, based on levels of Gr-1 expression, allowed for the 
identification of two distinct IL-17RB+ myeloid populations (Fig. 3.2c, 3.4a). A 
comparison of total cell numbers between naive and allergic animals identified 
significant increases in both Gr-1mid and Gr-1hi subsets in the lungs of allergic mice (Fig. 
3.4a), however the IL-17RB+ CD11b+ Gr-1mid population produced IL-4 and IL-13 while 
the Gr-1hi population did not (data not shown).  Isolation of the Gr-1mid subset by FACS 
identified a granulocytic population with a circular or partially segmented nuclei and 
relatively high nucleus to cytoplasm ratios (Fig. 3.4b).  These data inspired our next set 
of experiments, an investigation of IL-17RB’s involvement in the production of type 2 
cytokines in this granulocytic IL-17RB+ population. 
 
Figure 3.4: IL-17RB+ myeloid subsets are significantly increased in allergic airways 
disease.  (a) (g) Pulmonary IL-17RB+ CD11b+ Gr-1mid populations are significantly 
increased following allergen sensitization. (*P = 0.0026). Bars represent the mean ± 
s.e.m. for each group of 5 animals. (*P < 0.0026 versus naive).  Results are representative 
of two independent experiments. (b) Morphology of myeloid cells isolated from the lungs 










CD8- B220- IL-7Rα- Sca1- c-kit- (see Fig 2.1) and stained with Hematoxylin and Eosin 
(H+E). Scale bar 50 µm. 
 
Allergen sensitized Il17rb–/– mice exhibit decreased pathophysiology and type 2 
inflammation 
 
To further explore the overall role of IL-17RB in allergic asthma, Il17rb–/– mice 
were sensitized to allergen.  The loss of the IL-25–specific receptor protected Il17rb–/– 
mice from allergen-induced inflammation (Fig. 3.5).  Il17rb–/– allergic mice exhibited a 
dramatic reduction in peribronchial and perivascular inflammation, eosinophilic 
infiltrates, and mucus production (Fig. 3.5a).  Pulmonary expression of type 2 cytokines 
as well as the eosinophil–associated chemokine eotaxin were significantly decreased in 
lungs of Il17rb–/– mice (Fig. 3.5b).  RNA transcripts from bone marrow cultures 
demonstrated a similar reduction in type 2 responses, indicating a systemic reduction in 
type 2 cytokines (Fig 3.5c).  Furthermore, Il17rb–/– draining lymph node cells re-
stimulated with antigen produced significantly less type 2 cytokines than WT lymph node 
cells (Fig. 3.5d).  Interestingly, a short–term model of allergen sensitization that utilized 
fewer allergen challenges revealed no phenotypic differences in Il17rb–/– mice (although 
relative levels of cytokine mRNA in whole lung isolates trended as had been observed 
previously) (Fig 3.6) suggesting that IL-17RB is most relevant during more chronic 




Figure 3.5: Il17rb–/– mice are protected from allergen induced type 2 inflammation. 
(a) PAS staining of lungs from WT and Il17rb–/– mice following chronic allergen 
sensitization. Scale bar 200 µm.   (b) Lungs from allergic mice (n = 5 animals per group) 
were harvested 24 h post final allergen challenge and whole lung homogenates were 
analyzed for cytokine production by bioplex.  Bars represent the mean ± s.e.m. for each 
group (*P = 0.001, #P = 0.048, +P < 0.05 versus WT allergen).  (c) QPCR analysis of 
cytokines in whole bone marrow (*P < 0.05) (d) Draining lymph nodes from allergic 
mice (n = 5 animals per group) were harvested and pooled 24 h post final antigen 
challenge.  Cells were cultured in media alone or restimulated with 10 µL per mL 
allergen ± 10 ng per mL IL-25.  Supernatants were collected after 48 h and analyzed for 
cytokine production by bioplex.  Bars represent the mean ± s.e.m. from triplicate wells. 




Figure 3.6: Repeated allergen challenges are necessary for pulmonary recruitment 
of IL-25 responsive CD11b+ Gr-1+ myeloid cells. (a) Model used in a short-term model 
of allergen-induced asthma.  Mice received 3 challenges (as opposed to 6) and were 
assessed for recruitment of inflammatory cells to the lung by histology and flow 
cytometry.  (b) Il25 and Il17rb expression following short-term versus chronic allergen 
models. (c) H+E staining indicates that in a more acute setting, Il17rb–/– mice generate 
similar amounts of peribronchial inflammation as WT allergen sensitized mice.  Scale bar 
for upper row, 400 µm; lower row, 200 µm. (d) Flow cytometric analysis for CD4+ T 
cells and myeloid populations showed no differences between WT and Il17rb–/– allergen 
treated groups (n = 5 animals per group) after a shortened model of allergen sensitization. 
 
CD4+ T cell function is altered by loss of IL-17RB 
To address the relative importance of IL-17RB on cell types involved in the 
adaptive immune response to allergic inflammation, we focused our assessment on the 
function of CD4+ T cells and dendritic cells (DCs).  Using in vitro co–culture 
experiments, mature allergen pulsed bone marrow–derived WT and Il17rb–/– DCs were 
cultured with CD4+ T lymphocytes isolated from allergen sensitized WT or Il17rb–/– 
mice.  As Figure 3.7 indicates, both WT and Il17rb–/– DCs generated an equivalent 
response in WT CD4+ T cells, indicating that DCs from Il17rb–/– mice can function 
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properly to activate Th2 cytokine production. This result is consistent with flow 
cytometric data indicating that IL-17RB is either not expressed, or expressed at low 
levels, on DCs (data not shown).  Cytokine production in Il17rb–/– T cells, however, was 
significantly diminished compared to WT T cells, irrespective of DC source, WT or 
Il17rb–/–.  These data suggest that a component of the diminished inflammatory response 
observed in Il17rb–/– mice is related to a deficit in Th2 cell but not DC function. 
 
 
Figure 3.7: In vitro: Loss of IL-17RB alters T cell but not dendritic cell function.  
Il17rb–/– CD4+ T cells produce fewer type 2 cytokines than WT CD4+ T cells, 
irrespective of DC origin.  Mature bone marrow derived dendritic cells (BMDCs) 
cultured from 3 WT or 3 Il17rb–/– mice were pulsed with 10 µL per mL allergen for four 
h, and then co-cultured with WT or Il17rb–/– CD4+ T cells isolated from the pooled 
spleens of allergic mice (n = 5 mice per group), at 2x104 BMDCs and 2x105 CD4+ T cells 
per well.  Supernatants were collected after 48 h in culture and analyzed for protein by 
bioplex.  Bars represent the mean ± s.e.m. from triplicate wells (*P < 0.05).  These data 
indicate that IL-17RB is not necessary for the antigen-induced activation of previously 
activated T cells by DC. 
 
To address T cell function in vivo, we adoptively transferred CD4+ T lymphocytes 
(6 x 106 per mouse) from allergen-sensitized mice into Rag2–/– recipients. Our in vivo 
results paralleled our in vitro experimental findings.  Transfer of T cells from WT mice 
significantly upregulated mRNA expression of both Il25 and Tslp, as well as Ccl11 
(Eotaxin), Ccl17 (TARC), and its receptor Ccr4, whereas Il17rb–/– T cell transfer showed 
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significantly lower transcript levels (Figure 3.8a). While both WT and Il17rb–/– T cell 
recipients mounted a Th2 response to allergen, Th2 cytokine production in Il17rb–/– T 
cell recipients was significantly lower than that seen in WT T cell recipients (Figure 
3.8b).  Similar to our findings with allergen studies in WT and Il17rb–/– mice, recipients 
of Il17rb–/– T cells also exhibited a significant reduction in numbers of myeloid cell 
infiltrates following allergen challenge (Figure 3.8c).  Taken together, the results of these 
in vitro re-stimulation experiments, as well as in vivo adoptive transfer studies with Rag2–
/– mice, demonstrated that CD4+ T cell responses were altered in Il17rb–/– mice and could 
not efficiently transfer a type 2 immune response to Rag2–/– mice.  These data were 
similar to findings published by several investigators establishing a role for IL-25 in 
promoting T cell mediated type 2 responses. 
 
Figure 3.8: In vivo: Loss of IL-17RB alters T cell but not dendritic cell function.  
6x106 WT or Il17rb–/– CD4+ T cells isolated from the pooled spleens of allergic mice (n = 
5 mice per group) were adoptively transferred by tail vein injection into naive Rag2–/– 
mice.  Recipient mice received two IT allergen challenges, the first immediately 
following T cell transfer and the second 4 days later.  (a) mRNA analysis was performed 
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by QPCR on whole lung tissue from recipient mice (n = 4 mice per group) 24 h post final 
allergen challenge.  Bars represent the mean ± s.e.m. for each group, *P < 0.05.  (b) 
Lungs of Rag2–/– recipient mice (n = 4 animals per group) were harvested 24 h post final 
antigen challenge and whole lung homogenates were analyzed for cytokine production by 
bioplex.  Bars represent the mean ± s.e.m. for each group, *P < 0.01.  (c) Flow cytometric 
analysis of Rag2–/– mice following adoptive transfer of CD4+ T cells from allergic 
donors.  Bars represent the mean ± s.e.m. for each group, *P < 0.03.  Despite the ability 
of both WT and Il17rb–/– T cells to induce a type 2 inflammatory response, a significant 
reduction in overall pulmonary inflammation, and subsequent response to allergen, was 
observed in recipients of Il17rb–/– T cells compared to WT. This altered response affected 
the recruitment of other cells via a reduction in transcripts of allergen-associated 
chemokines like Ccl17 (TARC).  It also led to a significant decrease in myeloid infiltrates 
following allergen challenge, indicating that the absence of IL-17RB in CD4+ T cells led 
to a systemic deficiency in inducing a type 2 cytokine mediated inflammatory 
environment. 
 
IL-4 and IL-13 production in myeloid cells is abrogated by the absence of IL-17RB 
Flow cytometric analysis of inflammatory populations demonstrated no difference 
in numbers of CD4+ and CD8+ T lymphocyte subsets between the lungs of allergen 
sensitized Il17rb–/– or WT mice.  However, Il17rb–/– mice exhibited significant reductions 
in the CD11b+ Gr-1mid myeloid cells previously identified as a source of type 2 cytokines 
in allergic animals (Fig. 3.9a).  Intracellular cytokine staining of the CD11b+ Gr-1mid 
population verified that Il17rb–/– mice had a significantly reduction in type 2 cytokine 
producing cells relative to WT mice (Fig. 3.9b).  Reduced lymph node cytokine 
production, altered CD4+ T cell function, the reduction in type 2 cytokines, and a 
dramatic decrease in pulmonary myeloid cell infiltrates indicated that multiple cell types 




Figure 3.9: Type 2 cytokine production in CD11b+ Gr-1+ myeloid cells is IL-17RB 
dependent. (a) Flow cytometric analysis of lungs from allergic WT and Il17rb–/– mice (n 
= 5 animals per group).  Bars represent the mean ± s.e.m. for each group (*P < 0.03).  (b) 
Intracellular cytokine staining for IL-4 and IL-13 producing cells was performed in 
allergic WT and Il17rb–/– mice (n = 4 animals per group).  Results are gated on CD11b+ 
Gr-1mid cells.  Bars represent the mean ± s.e.m. for each group (*P < 0.05, #P < 0.0009).  
Data are representative of two independent experiments. 
 
Discussion 
The present study used a mouse model of chronic allergic asthma to identify both 
T and non–T IL-25 responsive cells involved in pulmonary inflammation.  While 
previous studies have established that targeting IL-25 leads to the reduction of type 2 
responses16,193,201, this study is the first to characterize how deficiency in IL-17RB 
reduces the pathology of allergic asthma induced by a common environmental allergen.  
Other reports, including one from our laboratory, have demonstrated that eosinophils 
produce IL-2511,14, thus linking IL-25 production to eosinophilia induced by the allergic 
response. These data are consistent with clinical studies, as peripheral blood mononuclear 
cells from patients with severe allergic rhinitis exhibit increased IL-17RB221, and 
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polymorphisms in IL-17RB have been associated with increased risk for severe 
asthma223.  Furthermore, a recent study has identified that allergen–induced expression of 
IL-25 and its receptor in atopic asthmatics correlates with disease severity222.  Il17rb–/– 
mice had reduced allergen–induced pathology, including a significant reduction in type 2 
cytokines primarily associated with the CD11b+ Gr1mid cells that were most prominent 
during persistent allergen–induced disease. 
Because IL-17RB+ subsets could be distinguished based upon their intensity of 
Gr-1 expression, and in light of the differing capacity for IL-4 and IL-13 production 
between Gr-1mid and Gr-1hi populations, IL-17RB+ Gr-1hi cells may have functions that 
overlap with other CD11b+ Gr-1+ populations, such as myeloid suppressor cells243,244.  A 
recent study reported that both IL-17RA and IL-17RB can be expressed on the surface of 
human neutrophils245.  
As evidenced by alterations in cytokine expression in lung, LN, and bone marrow 
populations, signaling through IL-17RB plays an important role in the biology of both 
innate and adaptive immune populations.  The adoptive transfer of CD4+ T cells 
demonstrated the systemic effects of a global absence of IL-25 signaling.  Il17rb–/– T 
cells not only exhibited reduced cytokine production when presented with antigen, the 
absence of an IL-25 receptor created a domino effect, whereby reduced cytokine 
production led to reduced inflammation, and diminished chemokine production from a 
less inflamed airway epithelium.  As flow cytometric data demonstrated, without IL-
17RB on T cells, chemokine transcripts were lowered in the lung and there was a 
significant reduction in the influx of type 2 cytokine producing myeloid cells identified in 
 62 
our model of chronic allergic inflammation.  This same population is absent in Il17rb–/– 
mice following allergen exposure as well. 
The recent identification of IL-25 and IL-33 responsive innate lymphoid cells 
offers evidence supporting the critical role innate immunity plays in the development and 
type 2 inflammatory responses, however these cells were not increased following allergen 
administration20-23.  Given our findings that IL-25 expression is upregulated during 
chronic, but not short–term allergen exposure, the IL-17RB+ myeloid population 
identified in these experiments may represent an arm of the innate immune system 
required for maintenance of the chronic inflammatory environment.  However, the 
resolution provided by these experiments does not enable comment on IL-25–dependent 
events that may occur in the absence of allergen.  These represent the topic of Chapter 5. 
The present study identifies a role for IL-25 in the development of allergic 
asthma.  One question raised by these results relates to the purity of the induced 
inflammatory response, specifically whether this type of “pure” type 2 inflammation is 
similar to the types of inflammatory stimuli commonly encountered in the environment.  
The most severe symptoms of respiratory syncytial virus (RSV), for example, are 
associated with excess mucus production, largely driven by the overproduction of IL-
13113.  In the case of RSV, increased IL-13 represents one component of a mixed 
inflammatory response that involves an upregulation of both IFNγ and IL-17A.  IL-25’s 
role in the mixed inflammatory environment created in response to RSV infection is the 








 Individuals who suffer severe respiratory viral infections in infancy and early 
childhood are at significantly increased risk for the development of childhood asthma and 
pulmonary disease, and respiratory syncytial virus (RSV) is a well–established cause of 
this phenomena.  The mechanisms by which RSV infection promotes the development of 
the asthma are not well understood, however reducing the incidence and severity of RSV 
infections reduces the likelihood that an individual will develop asthma.   The most 
severe pathology of RSV infection is associated with overproduction of type 2 cytokines, 
leading to mucus hypersecretion.  This study investigated the role of IL-25 in the 
development of RSV-associated immunopathology.  IL-25 was increased following RSV 
infection, and IL-25 blockade reduced RSV associated pathology and type 2 cytokine 
production.  Il17rb–/– mice demonstrated a dysregulated inflammatory response 
characterized by decreased Th2 but increased Th17 cytokine production.  The inhibition 
of IL-25 signaling also significantly reduced inflammation and cytokine production in a 
model of RSV driven asthma exacerbation.  These results indicate that IL-25 regulates 
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the inflammatory response to RSV infection and that its inhibition may enable a 
reduction in the severity of RSV–associated pulmonary inflammation.  
 
Introduction 
RSV is a ubiquitous pathogen and the most common cause of hospitalization in 
the first year of life82.  Upwards of 95% of children have been exposed to the virus by age 
two94,95, and although subsequent infections are generally less severe, RSV represents a 
difficult target for the adaptive immune system because T and B cell memory is not fully 
protective, and does not prevent reinfection from occurring throughout life96-98.  
Opportunistic infections with RSV can have significant impacts on elderly and 
immunocompromised populations99-101, and present with variable symptoms ranging 
from asymptomatic illness to bronchiolitis requiring hospitalization and, in the most 
severe cases, death due to respiratory failure.  Initial attempts to generate a vaccine 
against RSV ended in failure when individuals inoculated with an inactivated virus 
became hyper-responsive to subsequent RSV infection, causing profound type 2 
inflammation, mucus hypersecretion, and pulmonary eosinophilia102,103.  RSV’s clinical 
importance, and the absence of an effective vaccine, therefore makes understanding 
immune regulation of RSV infection an important are of research. 
The pathology of RSV infection includes significant airway epithelial damage, 
mucus hypersecretion, and increased type 2 cytokines in the lung113,114, similar in many 
ways to pathology associated with allergic asthma.  As with asthma, several investigators 
have linked this clinically relevant pathology not with direct effects of the viral infection, 
but with consequences of the host immune response115,116.  RSV infection can generate a 
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mixed inflammatory response in addition to type 2 inflammation.  This is the result of an 
induction of neutrophilic Th17 inflammation along with type 1 anti–viral responses117.  
Therefore, the dramatic surge in pathology that can accompany this viral infection in 
asthmatic patients is related to the additive effects of mixed Th1, Th2 and Th17 
inflammation. 
 IL-25 is an IL-17 family member that regulates multiple aspects of mucosal 
immunity by promoting type 2 inflammation and production of IL-4, IL-5, and IL-134.  
We investigated the role of IL-25 in the pathogenesis of RSV; specifically how inhibition 
of IL-25–mediated signals may alter the development of RSV-associated 
immunopathology.  Here we report that IL-25 is upregulated following RSV infection, 
and that peak cytokine expression corresponds with peak inflammation.  Our findings 
indicate that IL-25 plays an important role in the establishment of type 2 
immunopathology in RSV infection.  RSV–induced pathology, including inflammatory 
infiltrates, airway hyperreactivity, and lymph node cytokine production were attenuated 
by the inhibition of IL-25 signaling through the use of a blocking antibody and in Il17rb–
/– mice, indicating that Th2-associated pathology in RSV infection is IL-25–dependent.  
Using a model of allergic asthma, we further report that RSV–associated exacerbation of 
allergic airways disease is reduced in the absence of Il-17rb, and associated with a 
reduction in type 2 cytokine production.  Previous studies have identified an inverse 
relationship between the expression of IL-25 and IL-17A, and our findings support these 
assertions201,213,246.  Taken together, our data suggest that mucus hypersecretion, the most 
significant pathology associated with RSV infection, may be effectively managed 
through the tandem targeting of IL-25 and IL-17A. 
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Results 
 Clinically, the most severe sequela of both allergic asthma and RSV infection 
results from airway obstruction and subsequent ventilation-perfusion mismatch153,157,247.  
Type 2 cytokines, IL-13 in particular, act as primary mediators of mucus hypersecretion 
in both asthma and RSV infection, and IL-25’s ability to promote their production was 
therefore of great interest because the overproduction of type 2 cytokines has the highest 
correlation with poor clinical outcomes.  The mechanism by which viruses such as RSV 
induce type 2 inflammatory responses remains unclear.  In our initial experiments, we 
sought to determine whether IL-25 plays a role in the inflammatory response to RSV 
infection by utilizing a time course to measure Il-25 and Il17rb lung transcripts (Figure 
4.1).  Transcripts of both genes increased following infection, peaking between days 4 
and 8 and returning to baseline levels by day 12.  This pattern of expression corresponded 
to previous findings of peak inflammatory responses at day 6 post infection, and 






Figure 4.1: RSV infection induces upregulation of Il25 and Il17rb. BALBc mice were 
infected with RSV and transcripts of Il-25 and Il-17rb were assessed at days 1, 2, 4, 6, 8, 
and 12 post infection.  (a and b) Increasing expression of pulmonary IL-25 and IL-17RB 
transcripts mirror the inflammatory response induced by RSV infection. RSV induces 
peak levels of inflammatory cytokines on day 6 post-infection. Values represent the mean 
± s.e.m., n= 4 per group. 
 
Anti-IL-25 administration reduces RSV-associated pathology and LN cytokine 
production 
 
 To further investigate the role of IL-25 in the inflammatory response to RSV 
infection, mice were infected with RSV and treated with a polyclonal antibody to IL-25.  
The effects of anti–IL-25 therapy in these mice were assessed on day 10 post infection, 
corresponding to peak pathophysiology in our model.  RSV infected mice treated with 
anti-IL-25 antibody exhibited a significant reduction in airway hyperreactivity (Figure 
4.2a), as well as a significant reduction in the mucus-specific gene Gob5 (Figure 4.2b).  
Histologic analysis confirmed that inhibiting IL-25 reduced airway inflammation and 
mucus (Figure 4.3a), however it did not affect total numbers of inflammatory cells in the 




Figure 4.2: IL-25 blockade has significant effects on airway function. (a) Airway 
resistance following methacholine challenge was assessed in RSV infected mice at day 
10 post-infection. Values represent the mean ± s.e.m., n = 5 mice per group * P < 0.05.  
Data are representative of 2 independent experiments. B) QPCR of the mucus specific 
gene Gob5.  
 
In our next set of experiments, the draining LNs of RSV infected animals were 
collected and restimulated in vitro to assess the effects of IL-25 blockade on cytokine 
production (Figure 4.4).  RSV–infected LN cells from mice treated with control IgG 
produced type 2 cytokines in response to both RSV and recombinant IL-25, while LN 
cells from animals that had been treated with anti-IL-25 antibody showed dramatic 
reductions in production of both type 2 cytokines (Figure 4.4a-c), as well as IL-17A 
(Figure 4.4d) and IFNγ (Figure 4.4e).  Whereas culture with IL-25 further increased 
type 2 cytokine production in RSV restimulated LN cells from IgG treated mice, anti–IL-
25 treated LN cells exhibited blunted or absent responses to stimulation with both RSV 
and IL-25 stimulation.  We have previously shown that loss of IL-25–IL-17RB 
interaction does not affect antigen presentation (see Fig 3.7).  Therefore, these results 
indicate that IL-25 inhibition prevented the activation of RSV–specific T lymphocytes, as 
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cytokine expression from anti-IL-25 treated animals could not be restored by exogenous 
IL-25 or  RSV restimulation. 
 
 
Figure 4.3:  IL-25 blockade reduces airway mucus but not inflammatory infiltrates. 
(a) Representative lung histology from RSV infected mice treated with either control 
antibody or αIL-25, showing inflammation and mucus in the airway at day 10 post 
infection. Upper row scale bar 400 µM, lower row scale bar 100 µM.  (b) Quantification 
of leukocyte populations in the lung on D8 post-infection by flow cytometry. (c) Protein 
quantification of lung cytokines by Bioplex.  Anti-IL-25 treatment significantly reduced 
levels of IL-4.  Values represent the mean ± s.e.m., n = 5 mice per group.  Data are 




Figure 4.4: Anti-IL-25 treatment inhibits cytokine production in draining lymph 
nodes. (a–e) Draining LN cells were isolated on day 8 post infection and cultured for 48 
h in vitro ± RSV, ± IL-25.  Cytokine production was analyzed by Bioplex.  Values 
represent the mean ± s.e.m. of wells run in triplicate, with 400,000 cells per well.  Data 
are representative of 2 independent experiments. 
 
Loss of IL-17RB reduces RSV-associated immunopathology and dysregulation of 
LN cytokine production 
 
 To confirm our findings, Il17rb–/– mice were inoculated with RSV and their 
inflammatory response to viral infection was assessed.  Il17rb–/– mice exhibited 
diminished inflammation following RSV infection, including a reduction in airway 
inflammation (Figure 4.5a) and significantly reduced pulmonary type 2 cytokine 
transcripts (Figure 4.5b).  As was the case with anti–IL-25 therapy, cell numbers in WT 
and Il17rb–/– did not change following infection (data not shown).  However, cytokine 
production in draining LN cultures demonstrated the importance of IL-25 in regulating 
the inflammatory response to RSV infection (Figure 4.6).  Whereas production of the 
type 2 cytokines IL-4 and IL-5 were significantly decreased, the absence of IL-17RB was 
associated with a dramatic increase in IL-17A, as well as a more moderate surge in IFNγ 
production.  These findings are consistent with a previous study, in which an inverse 
relationship was reported between IL-17A and IL-25 expression in an OVA model of 





Figure 4.5: RSV-induced pulmonary inflammation is attenuated in the absence of 
IL-17RB. WT (C57BL6) or Il17rb–/– mice (n = 5 per group) were infected with RSV, and 
the inflammatory response was assessed at day 6 post infection. (a) Representative lung 
histology, stained with PAS and demonstrating reduced inflammation and mucus in RSV 
infected Il17rb–/– mice. Upper row scale bar 400 µM, lower row scale bar 100 µM.  (b) 
Lung QPCR of Il4, Il5, and Il13.  Transcripts of Ifng and Il17a were not significantly 




Figure 4.6: Il17rb–/– LNs exhibit dysregulated cytokine production following RSV 
infection. Draining LNs from WT and Il17rb–/– mice (n = 5 per group) were harvested 
and restimulated with RSV.  Supernatants were collected after 48 h in vitro and analyzed 
by Bioplex.  Values represent the mean ± s.e.m. of wells run in triplicate.  *P < 0.05. 
 
Viral exacerbation of allergic asthma is attenuated in the absence of IL-25 signaling 
 In our final set of experiments, we employed a shortened model of allergic asthma 
to study viral exacerbation with RSV (see Figure 2.2).  As we have shown previously, 
IL-25 plays an important role in the inflammatory response to environmental allergens 
(Chapter 3), however the involvement of IL-25 in the context of allergy appears to be 
dose-dependent and requires chronic exposure to manifest significant effects (see Figure 
3.6).  While we did not observe the type 2 cytokine producing myeloid population 
identified in Chapter 3 following RSV infection alone, we hypothesized that the viral 
exacerbation of pre-existing allergic disease may induce sufficient IL-25 production to 
trigger recruitment of myeloid cells. As has been discussed in Chapter 1, viral 
exacerbations of allergic asthma are of great concern to susceptible populations such as 
children, the elderly, and immunosuppressed individuals90,91,99-101.  The single most 
pathogenic component of RSV infection is the overproduction of mucus, which can block 
airways and require medical intervention or respiratory support in severe cases113,114.  
Underlying airway inflammation, such as that seen in asthma, necessarily reduces an 
individual’s ability to tolerate added airway obstruction from mucus production. 
We utilized a short–term, three challenge model of allergic disease (as described 
in Figure 3.6) to induce a moderate degree of pulmonary inflammation.  The use of a less 
severe allergen model enabled us to assess the additive effects of RSV infection.  WT and 
Il-17rb–/– mice were sensitized to allergen as previously described, inoculated with RSV, 
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and then challenged with allergen during the course of RSV infection.  To further 
simulate an exacerbation of underlying airways disease, we administered two of three 
allergen challenges following inoculation with RSV (see Figure 2.2).  The exacerbation 
of underlying allergic inflammation with RSV infection produced a patchy, 
heterogeneous inflammatory response (Figure 4.7), with both mononuclear and 
granulocytic infiltrates. The absence of IL-17RB had modest effects on reducing the 
overall inflammatory response.  Compared to WT animals, Il17rb–/– mice exhibited a 
reduction in airway inflammation following RSV exacerbation, however the most 
apparent difference between groups was the reduction in mucus production in the RSV 
exacerbated Il17rb–/– group (Figure 4.7).  Flow cytometric analysis of inflammatory 
subsets in the lung identified significant differences in only one population following 
viral exacerbation.  The myeloid population (here labeled as T2M cells) identified in 
Chapter 3 was significantly increased in WT mice inoculated with virus and absent in 
Il17rb–/– mice (Figure 4.8a).  The pathologic relevance of T2M cells are explored and 
discussed at length in Chapters 5 and 6, however it is important to note that mucus 
hypersecretion is associated with T2M IL-13 production, and a reduction in mucus is 
consistent with the absence of this population (see Figures 5.3, 6.3 6.4, and 6.5). 
As in previous experiments, the draining LN of WT and Il17rb–/– mice sensitized 
to allergen and inoculated with RSV were isolated and restimulated in vitro with allergen 
and RSV.  An analysis of cytokine levels from the supernatants of these cultures showed 
no differences in cytokine production between WT and Il17rb–/– mice upon restimulation 
with allergen and RSV (data not shown).  These data require further investigation to  
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Figure 4.7: Exacerbation of allergic airways disease by RSV infection. To model viral 
exacerbation in the context of allergic airways disease, WT and Il17rb–/– mice (n = 5 per 
group) were sensitized to allergen and infected with RSV.  Mice received 3 total allergen 
challenges, and inflammation was assessed on day 6 post RSV infection.  Representative 
PAS stained slides illustrating the inflammatory response. Left column scale bar 1,000 







Figure 4.8: Quantification of pulmonary immune populations following the 
exacerbation of allergic asthma by RSV.  WT C57BL6 and Il17rb–/–  mice were 
sensitized to allergen and inoculated with RSV to model viral exacerbation of underlying 
airways inflammation.  (a-j) Quantification of lung inflammatory populations by flow 
cytometry, characterized as follows: T2M cells (CD11b+ Gr1mid F4/80+ IL-17RB+, 
CD11c-, MHCII-, IL-5rα-, discussed at length in Chapters 5 and 6), eosinophils (CD11b+ 
Gr1hi F4/80- IL-17RB-, CD11c-, MHCII-, IL-5rα+) neutrophils (CD11b+ Gr1mid F4/80- IL-
17RB-, CD11c-, MHCII-, IL-5rα-), conventional DCs (CD11b+ Gr1lo F4/80- IL-17RB-, 
CD11cmid, MHCIImid, IL-5rα-), Monocyte/Macrophages (CD11b+ Gr1lo F4/80+ IL-17RB-, 
CD11c-, MHCII+, IL-5rα-), and Alveolar Macrophages (CD11blo Gr1lo F4/80- IL-17RB-, 
CD11chi, MHCIImid, IL-5rα-).  Lymphocytes were gated on CD3+ CD11b- cells, and 
included CD4+ T cells, activated CD4+ CD69+ T cells, CD8+ T cells, and activated CD8+ 
CD69+ T cells. (n = 5 mice per group, *P = 0.05, ** P = 0.013) 
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determine the effects of simultaneous stimulation with RSV and allergen.  Whereas 
previous experiments with Il17rb–/– mice demonstrated significant differences in LN 
cytokine production (see Figures 3.5, 3.7, and 4.6) between Il17rb–/– and WT mice, in 
this case the effect of simultaneous antigen stimulation did not have a similar effect.  This 
may be related to the mechanisms by which allergen and RSV are taken up and processed 
by APCs248-250, or to APC maturation following RSV stimulation (leading to decreased 
uptake of additional antigen), or it could be related to counterregulatory mechanisms 
associated with increased IL-17A production in RSV–specific T cells and type 2 cytokine 
production in allergen-specific cells201,251.  Future experiments will be necessary to 
resolve this discrepancy, however on the whole it appears that Il17rb–/– mice suffered a 
more mild form of asthma exacerbation than WT mice. 
 
Discussion 
The results of this study indicate that IL-25 may represent a target to inhibit the 
pathogenesis of severe lower respiratory tract infections, thereby decreasing the risk of 
developing airway disease by reducing the severity of the inflammatory response.  
Individuals predisposed to the development of recurrent wheeze, whether due to family 
history or pre–existing atopy, may benefit from reduced airway damage and pulmonary 
dysfunction in early life.  Childhood viral infections have multiplicative effects on the 
risk for an eventual asthma diagnosis64,92.  For example, individuals with sensitivities to 
house dust mite (HDM) are at an up to seven–fold higher risk for asthma if they 
experience a severe respiratory infection with either RSV or RV64.  Genetic 
predisposition also plays an important role.  Children hospitalized with RSV bronchiolitis 
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before their first birthday are at a five–fold increased risk of asthma if one parent has a 
history of allergic disease78. 
Based on diminished T cell responses to antigen specific stimuli, as well as 
blunted responses to IL-25, the results of this study indicate that anti–IL-25 
administration may inhibit T cell activation.  In Chapter 3, similar effects were observed 
in experiments assessing type 2 cytokine secretion by Il17rb–/– T cells.  However, it is 
clear that Il17rb–/– T cells are capable of responding to antigen and of producing large 
amounts of cytokine (as evidenced by their overproduction of IL-17A in response to RSV 
restimulation).  Taken together, these findings indicate that T cells may require activation 
prior to becoming IL-25 responsive, but that activation itself can occur in an IL-25 
independent manner.  Therefore IL-25 may act as an additional polarizing signal for 
antigen-dependent responses; enabling T cells to differentiate and mount a Th2 response 
in situations where IL-25 is being produced, such as allergic asthma and RSV infection18.  
An evaluation of pulmonary populations with the capacity to respond to IL-25 in an 
antigen-independent manner represents the topic of our next chapter. 
Palivizumab, a monoclonal RSV-specific antibody targeting the RSV F (fusion) 
protein, has been shown to offer passive immunization against RSV infection.  In light of 
the absence of an effective vaccine, it currently represents the most effective RSV 
prophylaxis in individuals with high risk of developing complications from RSV and its 
long-term sequelae252.  A prospective cohort study of palivizumab prophylaxis among 2-5 
year old patients identified significant protective effects associated with the prevention of 
early life lower respiratory tract infections79.  These included a reduction in 
hospitalizations, and an 80% reduction in the relative risk of developing recurrent 
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asthma-associated wheeze among patients with no family history of atopy. However, 
atopic children, or children with at least 1 atopic parent, were not similarly protected 
from wheeze onset.  Based on these findings, the authors conclude that early life RSV 
infection and the later development of recurrent wheeze are linked, but that the 
mechanism by which RSV leads to later airway dysfunction is atopy–independent79,253. 
Our data suggest that mucus hypersecretion, the most significant pathologic 
component associated with RSV infection and asthma exacerbation, may be effectively 
managed through the tandem targeting of IL-25 and IL-17A.  The cytokine specific 
receptors of these molecules require common adapter proteins for signal 
transduction176,203-205, and a recent report identified a peptidomimetic–based strategy that 
targeted the shared adapter molecule Act1254.  A CC loop mimetic of the Act1 SEFIR 
domain effectively blocked interactions between Act1 and the IL-17A and IL-25 
receptors, thus inhibiting both cytokines with one compound.  In the context of RSV 
infection, where a dysregulated inflammatory response drives disease pathology, the 
ability to regulate oppositional inflammatory signals could represent a powerful tool for 
preventing unwanted consequences of viral infection. 
The fact that the myeloid population first described in Chapter 3 is significantly 
increased in the context of viral asthma exacerbation represents an interesting finding that 
links the type 2 inflammation of viral pulmonary infections to that seen in allergic 
asthma.  This suggests that some synergy between allergic and viral disease, likely 
associated with IL-25 expression, drives their recruitment to the airway.  The 
identification of myeloid cells provides further evidence for their potential pathologic 
relevance, and supports the hypothesis that IL-25 is a critical mediator of pulmonary type 
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2 inflammatory responses.  These findings are especially intriguing given that numbers of 
other inflammatory populations did not differ between virally exacerbated allergic WT 
and Il17rb–/– mice, yet Il17rb–/– mice had reduced mucus in their airways.  Our next set of 
experiments sought to evaluate the role of IL-25 in promoting antigen-independent 
inflammatory responses.  As the results in Chapters 5 and 6 will indicate, the IL-25 
dependent promotion of a myeloid population in the context of viral exacerbation may 








Using an antigen–independent model of IL-25 induced inflammation, we 
identified IL-17RB+ CD11b+ Gr-1mid cells, previously observed in the context of chronic 
allergen exposure, as the primary IL-25–responsive population in the lung.  Subsequent 
experiments verified these cells as a source of IL-4 and IL-13 in response to IL-25 
administration, and established a unique combination of cell surface antigens that mark 
them as distinct from other granulocytic subsets.  Based on the production of type 2 
cytokines, a combination of distinct surface antigens, and characteristic granulocytic 
morphology, we termed this population Type 2 Myeloid (T2M) cells.  Microarray 
analysis identified T2M cells as readily distinguishable from other myeloid populations, 
and most closely related to eosinophils.  Taken together, these findings mark T2M cells 
as a distinct IL-4 and IL-13 producing IL-25 responsive granulocytic subset. 
 
Introduction 
While the three granulocytic subsets, neutrophils, eosinophils, and basophils, are 
derived from a common progenitor, the stage in development at which these populations 
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diverge is a matter of some debate.  Reports have identified discrete progenitor 
populations for eosinophils and basophils that cast doubt upon the functional utility of 
describing these populations as sharing a common granulocytic-monocyte progenitor 
(GMP).  In 2009, Mori et al. reported a discrete eosinophil lineage progenitor in humans, 
characterized as IL-5rα+, but sharing other progenitor cell surface markers, which gave 
rise exclusively to eosinophils255. Based on these findings, the authors concluded that 
eosinophils should be excluded from the human CMP lineage and recognized as an 
independent subset.  These findings somewhat mirrored those of a separate group, which 
identified eosinophil-committed progenitors in murine bone marrow as also expressing 
IL-5rα144.  Basophil-committed progenitors were subsequently identified as originating 
from GMPs in response to IL-3, and highly expressing FcεR1256.  The identification of 
receptor expression associated with cell fate implies that granulocytic subsets may 
diverge from a common ancestor either contemporaneous to or soon after the CMP stage.  
This early divergence may necessarily limit the functional and/or phenotypic plasticity 
between granulocytic subsets. 
 Given our findings that IL-25 expression is upregulated by repeated but not 
short-term allergen exposure, the IL-17RB+ myeloid population we have identified in the 
allergic lung may represent an innate immune population involved in the maintenance of 
a chronic inflammatory environment.   This population has a granulocytic morphology 
and produces IL-4 and IL-13, however it does not readily align itself morphologically or 
functionally with neutrophils, eosinophils, or basophils.  Our next set of experiments 
sought to characterize IL-25 dependent pulmonary inflammation, specifically role of IL-
25 in the recruitment of type 2 cytokine producing myeloid cells to the airway, in order to 
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better understand the origin and phenotype of these cells as well as other IL-25 
responsive cell types. 
The production of type 2 cytokine(s) by a myeloid population is by no means 
unprecedented.  Several populations have been associated with IL-4 production, 
including basophils, eosinophils, mast cells, and NK cells19,226,257-260.  However, IL-25 
responsive myeloid cells have remained an elusive target since they was first identified as 
a pathologically relevant population in T and B cell deficient Rag2–/– mice4,5.  Our effort 
to characterize T2M cells was greatly aided by the use of an IL-17RB–specific mouse 
anti–mouse antibody, which was not available to previous investigators.  Here we report 
that pulmonary IL-25 administration increases T2M cells in multiple tissues, including 
lung, bone marrow, spleen, and peripheral blood, and promotes the recruitment of T2M 
but not other IL-17RB+ cell types to the lung.  Our findings indicate that T2M cells are 
readily distinguishable from other type 2 associated inflammatory cells, and represent a 
novel IL-25–responsive population. 
 
Results 
IL-25 induces type 2 inflammation with allergic asthma–like pathology 
Our investigation of IL-25–dependent allergic responses suggested the importance 
of an innate myeloid population as a source of type 2 cytokines during chronic, allergen–
induced inflammation.  In order to disentangle the relative contributions T cell mediated 
responses from those of the myeloid population, we adapted a model of antigen–
independent IL-25–induced inflammation to directly assess the effects of IL-25 on type 2 
cytokine producing cells in vivo, thereby avoiding the confounding pro–inflammatory 
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effects of antigen–specific activation193.  Recombinant murine IL-25 was instilled into the 
airways of IL-4–IRES–eGFP (4get) mice.  4get mice express GFP in cells in which the 
IL-4 promoter is transcriptionally active, thereby enabling the identification of cells 
poised to produce type 2 cytokines261. As has been reported previously, the intra-tracheal 
administration of IL-25 induced a type 2 type inflammatory response, characterized by 
airway hyperreactivity, eosinophil infiltrates, mucus production, and the upregulation of 




Figure 5.1: Intra-tracheal administration of IL-25 induces antigen-independent type 
2 inflammation. 4get mice (n = 4 animals per group) were IT dosed with vehicle or 0.5 
µg IL-25 for 4 days, and the inflammatory response was investigated 24 h post final IT.  
(a) Airway hyperreactivity was assessed by plethysmography, reported as baseline 
pressure versus peak pressure following methacholine injection. (n = 3 mice per group, 
*P < 0.05).  (b) Lungs were harvested for histological analysis and paraffin sections were 
stained with PAS.  Scale bar 200 µm.  (c) mRNA analysis of lungs from 4get mice for 
Il25, Il17rb, and the type 2 cytokines Il5 and Il13, analyzed by QPCR (*P < 0.05). All 




IL-25–induced inflammation identifies Type 2 Myeloid (T2M) cells as a source of 
type 2 cytokines 
 
The analysis of cell–specific GFP/IL-4 expression in 4get animals suggests that 
CD11b+ Gr-1mid IL-17RB+ myeloid (T2M) cells are the primary IL-25 responsive 
population in the lung (Fig. 5.2).  CD4+ T cells, a source of IL-4 during the antigen–
specific inflammatory response, do not respond to IL-25 without prior activation.  
Likewise, while innate IL-25 responsive lymphoid populations have been identified in the 
gut using 4get reporter mice22, these populations do not increase in number or 
demonstrate an induction of GFP/IL-4 expression following pulmonary IL-25 instillation.  
The myeloid population exhibited a dramatic increase of GFP/IL-4 in response to IL-25 
(Fig. 5.2a), with approximately 80% of GFP/IL-4+ cells being CD11b+.  Of these myeloid 
cells, the CD11b+ Gr-1mid IL-17RB+ subset, termed T2M cells to describe their 
propensity for type 2 cytokine production, demonstrated particularly dramatic enrichment 
for GFP/IL-4 expression.  While IL-25 treated mice showed no increase numbers of other 
GFP/IL-4+ populations, there was a significant increase in CD11b+ Gr-1mid infiltrates 
(Fig. 5.2b).  Figure 5.2c illustrates that among the CD11b+ Gr-1mid population, all GFP+ 
cells were also IL-17RB+, indicating that IL-25 acts on IL-25 responsive myeloid cells in 
part by activating transcription at the IL-4 promoter.  Flow cytometric analysis further 
confirmed that the predominant pulmonary source of IL-13 following IL-25 
administration were also T2M cells (Fig. 5.2d).  Innate lymphoid Lin- c-kit+ Sca-1+ IL-
17RB+ cells, a source of IL-25-induced IL-13 in the gut during helminth infection, were 
not altered by pulmonary IL-25 administration (Fig. 5.2d). 
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Figure 5.2: T2M cells represent the primary source of type 2 cytokines following 
pulmonary IL-25 administration.  4get mice (n = 4 animals per group) were IT dosed 
with vehicle or 0.5 µg IL-25 for 4 days, and the inflammatory response was investigated 
24 h post final IT.  (a) Histograms of lung tissue from 4get mice treated with vehicle or 
IL-25, gated on total lung, CD11b+, T2M, CD4+ Lymphocytes, and Lin- Sca+ c-kit+ cells 
respectively.  (b) GFP+ and CD11b+ Gr-1mid populations in the lung were assessed by 
flow cytometry, (*P < 0.026).  (c) Pulmonary IL-17RB+ CD11b+ GFP/IL-4+ cell numbers 
following IL-25 administration.  Data are representative of two independent experiments.  
(d) Pulmonary IL-13+ populations following IL-25 treatment (n = 5 animals per group, 
*P = 0.038).  
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To further verify that myeloid cells were producing type 2 cytokines in response 
to IL-25 administration, we isolated T2M cells from the lungs of IL-25 treated mice (see 
Fig. 2.3) and assessed type 2 transcripts in this population. T2M cells exposed to IL-25 in 
vivo exhibited dramatic increases in Il4 and Il13 transcripts, whereas Il5 was derived 
from a CD11b- cell population that remains ill-defined in our studies (Fig. 5.3a-c).  In 
addition to the pulmonary effects of intra–tracheal IL-25 administration, T2M cells were 
also identified in the bone marrow of 4get mice following IL-25 treatments (Fig. 5.4), as 
well as in spleen and peripheral blood.  Thus, IL-25 had both local and systemic effects 
linked to development of T2M cells. 
 
 
Figure 5.3: IL-25 induces T2M expression of Il4 and Il13 but not Il5. (a–c) QPCR 
analysis of Il4, Il5, and Il13 transcripts in T2M cells. Cells were isolated from C57BL/6J 
mice dosed with 0.5 µg IL-25 for 4 days (n = 5 animals per group), and plated in 
triplicate.  T2M cells were isolated using MACS magnetic bead enrichment followed by 
FACS.  mRNA was isolated from naive C57BL/6J mice, CD11b depleted lung from IL-
25 treated mice, and T2M cells isolated from IL-25 treated mice.  All data are presented 




Figure 5.4: Pulmonary IL-25 administration induces IL-4 expression in myeloid 
bone marrow cells. 4get mice (n = 4 mice per group) were IT dosed with vehicle or 0.5 
µg IL-25 for 4 days.  The bone marrow response to pulmonary IL-25 administration was 
assessed.  (a) Pulmonary IL-25 administration induces a type 2 inflammatory response in 
bone marrow CD11b+ IL-17RB+ cells.  Representative flow plot of CD11b+ bone marrow 
from 4get mice treated with vehicle or IL-25.  (b) The percentage of CD11b+ Gr-1+ IL-
4/GFP+ IL-17RB+ bone marrow cells is increased by pulmonary IL-25 administration. 
Bars represent the mean ± s.e.m. for each group of mice, *P = 0.0008).  Data are 
representative of two independent experiments.  (c) GFP+ CD11b+ CD4- bone marrow 
cells were isolated by FACS and H+E stained. IL-4/GFP+ myeloid cells from IL-25 
treated 4get mice have similar morphology to T2M cells isolated from lungs of allergic 
mice.  Scale bar 50 µm.  (d) IL-4/GFP+ myeloid cells produce IL-4.  Whole bone marrow 
from IL-25 treated 4get mice (n = 4 mice per group) was pooled, isolated by FACS for 
GFP+ CD11b+ CD4- cells, and cultured in vitro with 10 ng per mL IL-25 for 48 h.  
Supernatants were analyzed by bioplex.  Bars represent the mean ± s.e.m. for CD11b+ 
GFP- and CD11b+ GFP+ cells, plated in triplicate. 
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T2M cells exhibit a distinct pattern of cell surface antigen expression 
Our data thus far suggest that T2M cells represent a distinct, IL-25 responsive 
granulocytic subset.  To confirm these findings, we assessed T2M cells for expression of 
cell surface antigens associated with cell-type specific distribution, as well as 
immunologic functions including activation, costimulation, antigen presentation, 
migration, and adhesion.  The resulting data confirm that pulmonary T2M cells are 
defined by a distinct combination of cell surface antigens, and can be characterized as 
CD11b+ Gr-1(Ly6C/G)mid, IL-17RB+, FcγR (CD16/CD32)+, F4/80mid, CD80+ (Fig. 5.5).  
Similar expression patterns were observed in T2M cells derived from other tissues, 
including spleen, bone marrow, and peripheral blood (data not shown). 
Because T2M cells have a granulocytic morphology, we evaluated the expression 
of surface antigens considered to be specific for each of the three granulocytic 
populations: neutrophils, eosinophils, and basophils (Fig. 5.5).  T2M cells did not express 
the neutrophil–specific receptor CXCR2, nor did they express basophil markers including 
CD49b or FcεR1a.  T2M’s did not express the eosinophil marker CCR3, however they 
did exhibit low expression of IL-5rα (although it is important to note that the eosinophils 
present in these analyses demonstrated approximately three logs more intense expression 
for this marker, at ~105 versus ~102).  FACS isolated T2Ms did not produce detectable 
transcripts of neutrophil or eosinophil–associated enzymes, including myeloperoxidase, 
major basic protein, or eosinophil peroxidase (data not shown), further supporting them 
as a separate granulocytic population.  Finally, T2M cells did not express antigens 
associated with innate lymphoid subsets, including c-kit, Sca-1, and the IL-33 receptor 
ST2, indicating that they are a separate innate type 2 cytokine producing population. 
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Figure 5.5: Patterns of surface antigen expression define T2M cells as a distinct 
granulocytic subset. Characterization of pulmonary T2M cells by cell surface marker 
expression.  4get mice were challenged with intra-tracheal IL-25 to induce recruitment of 
T2M cells to the lung.  T2M cells were identified by gating on CD11b+ Gr1mid IL-17RB+ 
GFP/IL-4+ cells, and expression of various surface markers was then assessed.  Gray 
shaded area: isotype, red line; T2M cells. Data are representative of 2 independent 
experiments. 
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Microarray analysis identifies T2M cells as a distinct granulocytic subset 
In an effort to fully characterize T2M cells, and to assess whether they are truly a 
distinct granulocytic subset, we employed our antigen–independent model of IL-25–
induced type 2 inflammation to induce T2M cells to the lung.  We isolated four myeloid 
populations from whole lung tissue; T2M cells, eosinophils, neutrophils, and monocytes 
(see Fig. 2.4).  Microarray analysis of total RNA from T2M cells compared to other 
myeloid populations (Fig. 5.6a-c) confirm that T2M cells represent a distinct 
granulocytic subset with a gene expression profile most closely related to eosinophils.  
Based on the large amount of variation observed between T2M cells and other assessed 
populations, we classified differences in gene expression as a three–fold or greater 
change in expression profile, with the added constraint the expression level of at least one 
cell subset was at least 26 or more (these parameters were suggested by the University of 
Michigan Microarray Core, and are more strict than their usual two-fold change cutoff). 
Based on these criteria, the T2M population had differential expression at 2299 
loci when compared to eosinophils and 2057 loci when compared to neutrophils (Fig. 
5.6b).  As one might predict given their differing morphologies and cell surface receptor 
expression patterns, the T2M population was most different from macrophages, with 
4324 differentially expressed loci.  Hierarchical analysis of T2M cells versus other 
examined cell types indicates that they are most closely related to, but still readily 
discernable from, eosinophils in terms of their expression pattern (Fig. 5.6a).  In addition, 
principal components analysis of each array sample indicated that T2M cells are a 
discrete subset, which share the highest degree of relatedness (in this case expressed 




Figure 5.6: Microarray expression profiles define T2M cells as a distinct 
granulocytic subset. (a) Hierarchical clustering analysis and heat map generated from 
microarray analysis of pulmonary T2M cells compared to eosinophils, neutrophils, and 
macrophages. Colors illustrate fold changes among 1,880 probes for which T2M cells 
exhibited a minimum 3 fold difference in expression from 2 or more cell types, and an 
average expression value of at least 26, normalized to average T2M expression levels. (b) 
Venn diagram illustrating differences in locus expression between T2M cells and other 
myeloid populations.  366 probes were differentially expressed between T2M cells and 
all cell types analyzed, 1,880 probes differed between T2M cells and at least 2 of the 
comparison populations. (c) Principal components plot illustrating relative degrees of 
relatedness between populations analyzed by microarray demonstrates that the subset 
most closely associated with T2M cells are eosinophils.  Red dots: T2M cells, light blue: 
eosinophils, green: macrophages, purple: neutrophils. 
 
T2M cells in the lung are non-proliferative 
 The identification of a novel granulocytic subset raises many questions related to 
how T2M cells may be incorporated into the hierarchy of myeloid subsets or progenitor 
populations.  In an effort to determine whether the T2M cells recruited to the lung in the 
context of high IL-25 are actively proliferating, and therefore may represent a 
phenotypically plastic population capable of differentiation or expansion into a separate 
granulocytic subset, 4get mice were treated (as in previous experiments) with intra–
tracheal IL-25.  On the final day of IL-25 administration, recipient mice were given an 
intra–peritoneal injection of EDU to track proliferating cells.  EDU is a thymidine 
analogue that is incorporated into replicating DNA, therefore EDU offers a means to 
identify proliferating cells via the detection of newly synthesized DNA262. Flow 
cytometric analysis of whole lung cells 18 hours after final IL-25 administration indicated 
that approximately 99% of T2M cells in the lung had not undergone proliferation in the 
time since EDU administration (Figure 5.7).  Therefore we conclude that high levels of 
IL-25 in an end organ site do not induce T2M cell expansion at that site, and T2M cells 
do not proliferate in the lung. 
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Figure 5.7: Pulmonary T2M cells are non–proliferative. IL-25 treated 4get mice (n = 
6) were injected IP with EDU following their fourth and final IL-25 challenge, and 
proliferation among lung cells was assessed 18 h later (a) Representative histograms of 
whole lung, T2M, CD4+ and CD8+ T cells following EDU administration.  Gates indicate 
the percentage of each population in which cells have replicated DNA, indicating active 
proliferation.  (b) Percentage of proliferating cells in the lung following IL-25 




 This study is the first to identify the T2M cell, an IL-25 responsive IL-4 and IL-13 
producing granulocyte.  This population, first observed in the context of chronic allergic 
lung disease, is the primary IL-17RB+ population recruited during conditions 
characterized by increased levels of IL-25.  While these cells have been studied most 
extensively in the lung, we have also identified them in all tissues assessed to date, 
 97 
including spleen, bone marrow, and peripheral blood.  The systemic circulation of bone 
marrow derived T2M cells implies that, in addition to allergic asthma, several other 
diseases associated with elevated IL-25 levels and type 2 inflammation may involve an 
influx of T2M cells.  These include diseases of epithelial tissues such as atopic 
dermatitis173,220, hypereosinophilic syndromes such as Eosinophilic Esophagitis263, and 
autoimmune disorders such as Churg-Strauss syndrome14,264. 
 The data provide evidence for the importance of T2M cells in promoting 
pathology resulting from IL-25 mediated type 2 inflammation.  However, they do not 
address the sufficiency of these cells to promote inflammatory responses, nor do they 
address how T2M cells may be involved in chronic allergic asthma.  T2Ms are a unique 
population, but several questions remain regarding their role in the context of innate 
immunity.  Based on the data presented herein, it could be argued that these cells are 
defined as much by what they lack as by their phenotypic and functional characteristics.  
The absence of surface antigens related to other myeloid subsets, specifically other 
granulocyte populations (eosinophils, neutrophils, and basophils), coupled with the lack 
of detectable cell-specific transcripts by QPCR provides evidence that T2M cells are 
unlike other defined myeloid subsets. 
Likewise, the production of IL-4 and IL-13, but not IL-5, differentiates T2Ms 
functional from innate lymphoid populations, which are known to produce IL-5 and IL-
13, but not IL-420-23.  A recent study has identified an innate lymphocytic population in 
the gut, lung, and nasal polyps of humans, further supporting their potential role in 
human disease237.  In our studies, this population was present at low numbers in the lung, 
and did not increase following IL-25 administration.  Previous reports have identified 
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other non–lymphoid populations as sources of type 2 cytokines that can contribute to the 
allergic environment, including basophils, mast cells, eosinophils, and 
macrophages76,77,227,229,257,258,260,265-268.  We did not detect significant IL-17RB expression 
in any of these populations in the lung.  Thus, it appears there are both Lineage+ and 
Lineage- IL-25 responsive cells whose recruitment may depend upon the type of mucosal 
surface (gut versus lung), both with the capacity to produce type 2 cytokines in an 
antigen–independent manner. 
T2M morphology also offers clues as to their appropriate classification among the 
other myeloid subsets.  T2M cells resemble an immature granulocyte, and appear at first 
glance to be similar to banded neutrophils (also known as metamyelocytes).  It is their 
inability to be classified with conventional labels that marks T2M cells as a unique 
population.  Microarray analysis adds further weight to the T2M as being different from 
other myeloid populations.  It links T2M most closely to eosinophils, and provides a great 
deal of information that could offer additional insight into T2M biology.  The chemokine 
receptors important for T2M functions have not yet been determined, and further 
investigation of these data may yield insight as to chemokine receptors important for 
T2M cell migration and recruitment to distant inflammatory sites.  Interestingly, 
microarray data indicate that the T2M population is enriched in expression of genes 
associated with all three comparison populations, as well as transcripts of some proteins 
(CCR3 and IL-5rα, for example), that were not expressed at the cell surface.  This may 
relate to the maturity of the T2M population, or to post–translational regulatory events 
that prevent these proteins from being expressed.  As we have previously discussed, IL-
5rα is expressed early in eosinophil progenitor development, prior to migration from the 
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bone marrow144,255.  The potential significance of mRNA expression in the absence of 
cell surface expression, coupled with the overall similarities between T2M and 
eosinophilic subsets, is further discussed in Chapter 7. 
 It is unknown whether T2M cells may differentiate into one of the 3 major 
granulocytic populations, however our data indicate that these cells are not actively 
proliferating, suggesting that they are migrating directly from the bone marrow during 
conditions with elevated IL-25 and not expanding outside the bone marrow.  The 
identification of T2Ms in bone marrow, and the finding that the population of bone 
marrow derived T2Ms rapidly increases upon pulmonary IL-25 administration, suggests 
the presence of important and as yet undetermined feedback loops capable of dynamic 
regulation of T2M granulopoiesis, including dramatic surges in T2M production upon 
receipt of the appropriate stimuli.  The fact that T2M cells in the bone marrow can 
actively secrete IL-4 upon IL-25 stimulation implies that they are functionally 
differentiated prior to their exit from the bone marrow niche.  This may represent a 
critical aspect of T2M function; the ability to differentiate quickly, migrate to an area 
with increased IL-25, and secrete type 2 cytokines upon arrival and IL-25 stimulation.  
The pathologic relevance of T2M cells, including their potential relevance of human 




The Pathologic Relevance of T2M Cells: Steroid Resistance, Mucus 





This set of experiments investigated the potential pathologic significance of T2M 
cells.  Given data indicating that T2Ms represent a distinct granulocytic population, as 
well as evidence linking the presence of T2Ms to asthmatic pathology, we hypothesized 
that T2M cells may represent a previously unrecognized, pathologically relevant IL-25–
responsive population.  The results of our investigation offer two pieces of data in 
support of this hypothesis.  The first is that IL-25–induced type 2 inflammation is steroid-
resistant, and T2M cells are insensitive to high dose dexamethasone administration.  The 
second is that the adoptive transfer of T2M cells is sufficient to induce mucus 
hypersecretion and Il-13 in otherwise IL-25–insensitive Il17rb–/– recipients.  In a separate 
clinical study, an IL-17RB+ granulocytic population analogous to T2M cells was 
identified in human peripheral blood.  This population produced IL-4 and IL-13, and was 
significantly increased in allergic asthmatics compared to non-asthmatic volunteers.  
These findings support T2M cells as a pathologically relevant granulocytic population 
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In the past 5 years several groundbreaking discoveries have been made regarding 
the importance of type 2 cytokine producing innate immune cells and regulation of the 
inflammatory response in mucosal tissues.  Initially these centered on NBNT type 2 
cytokine producing populations5,226,241.  More recently investigations have focused on the 
importance of innate lymphoid cells in the clearance of intestinal helminth infections20-23.  
The importance of innate lymphoid populations in mediating intestinal type 2 
pathologies, when compared to with our findings that an entirely separate population of 
T2M cells are recruited in the context of IL-25–associated pulmonary pathologies such as 
allergic asthma, naturally led us to question to what extent T2M cells may contribute to 
the pathogenesis of asthma. 
While a juxtaposition of T2M and innate lymphoid biology is not necessarily an 
equivalent comparison, reports have indicated that relatively minute numbers of type 2 
cytokine producing innate lymphoid populations are sufficient to alter disease 
phenotypes235.  For example, a recent study identified an estimated 1,500 lymphoid cells 
in the lung following influenza infection, and attributed significant disease modifying 
effects to this population236.   Our initial characterization of IL-17RB+ myeloid subsets 
(defined as T2M cells in later experiments) indicated that between 50–70 thousand T2M 
cells are present in a single lobe during chronic allergen-induced airways disease (see 
Figs 3.4a and 3.9b).  FACS isolation of T2M cells from lungs of IL-25 treated mice 
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consistently yields between 250–300,000 cells per mouse at 75% efficiency (data not 
shown), implying that IL-25–mediated inflammation results recruits a population of 
~400,000 pulmonary T2M cells.  This represents a dramatic influx of T2M cells 
compared to the naive pulmonary environment, and this myeloid IL-17RB+ population 
overwhelmingly outnumbers innate lymphoid populations in these same tissues (see Fig 
3.2).  Given their ability to produce IL-4 and IL-13, as well as their predominance in lung 
tissues in the context of increased IL-25 expression, we hypothesized that T2M cells 
represent a significant and previously unrecognized component of the type 2 
inflammatory response promoted by IL-25.   
To test our hypothesis, we evaluated the potential importance of T2M cells 
through three independent experimental approaches.  The first investigated T2M 
responses to corticosteroids, the front line anti–inflammatory drug in asthma 
exacerbations75.  The second focused on the sufficiency of T2M cells to promote type 2 
inflammation in the lung.  Our third mode of investigation aimed to determine whether a 
population analogous to T2M cells is present in humans, specifically those individuals 
with allergic airways disease.  The results of these experiments provide strong evidence 
that T2M cells represent a pathologically relevant component of IL-25–mediated disease 
with the potential to alter clinical manifestations of allergic asthma. 
 
Results 
IL-25-induced inflammation and T2M cell responses are steroid resistant 
To examine potential clinical implications of type 2 cytokine production in the 
T2M population, we examined how steroid treatment affected IL-25–induced pulmonary 
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inflammation.  Granulocytes, neutrophils in particular, are known to be resistant to the 
pro-apoptotic effects of corticosteroids32-36,163.  Steroid–resistant neutrophilic infiltrates 
have been implicated as a major cause of inflammatory pathology in the context of Th17 
inflammation, and have also been linked to the severe pathology associated with steroid–
resistant asthma.  The relevance of T2M cells in promoting type 2 inflammation and 
severe asthma pathology would be supported if these cells, like neutrophils, were also 
resistant to steroid administration. 
To focus on T2M–mediated inflammatory responses, 4get animals were treated 
with IL-25 as in previous experiments, with or without dexamethasone.  Histologic 
examination (Fig. 6.1a) and measurements of airway hyperreactivity (Fig. 6.1b) 
indicated that IL-25–induced responses were not significantly altered by dexamethasone. 
QPCR analyses demonstrated significant increases in type 2 cytokines, mucus genes, and 
Il17rb were also unaffected by dexamethasone administration (Fig. 6.1c).  Flow 
cytometric analysis measured equivalent numbers of IL-25–induced GFP/IL-4+ myeloid 
cells in animals treated with or without the glucocorticoid (Fig. 6.1d,e).  As was shown in 
Fig 5.2, antigen independent IL-25 administration significantly increased pulmonary 
myeloid but not lymphoid populations, which are known to be steroid–sensitive.  To 
verify that dexamethasone treatment was effective, we examined splenic cell subsets 
(Table 6.1).  Dexamethasone significantly reduced total splenocytes, with a specific 
reduction in CD4+ and CD8+ T cells as well as eosinophils, but had no effect on splenic 
T2M cells.  Overall these data present a striking finding that the IL-25–induced T2M 





Figure 6.1: T2M cells are steroid resistant. (a) Representative PAS staining indicates 
IL-25-induced mucus production in 4get mice (n = 5 per group) is not altered by 
dexamethasone administration.  Scale bar 400 µm; inset 100 µm. (b) Airway 
hyperreactivity (*P < 0.01 versus methacholine treated vehicle).  (c) QPCR analysis of 
whole lung following dexamethasone treatment.  (d) Representative flow plots of 
GFP/IL-4+ CD11b+ Gr-1mid pulmonary populations.  (e) Total numbers of pulmonary 
GFP/IL-4+ cells.  Bars represent the mean ± s.e.m. of 4 mice per group.  *P < 0.01 versus 











Table 6.1: Splenic T2M cells are increased following pulmonary IL-25 
administration and are not altered by dexamethasone administration.  Flow 
cytometric analysis of splenic populations illustrates the effect of dexamethasone (n = 4 
mice per group).  4get mice were treated with vehicle, IL-25, or IL-25 and 3mg kg-1 
dexamethasone.  IL-25 administration significantly increased numbers of T2M cells but 
had no effect on other splenic populations.  In contrast, treatment with dexamethasone 
significantly reduced total cell numbers, CD4+ and CD8+ T cells, and eosinophils, but had 











In separate experiments, we utilized the allergen model previously described in 
Chapter 3 to investigate the effects of high dose dexamethasone administration on 
antigen–dependent inflammation.  To inhibit IL-25–dependent inflammation in this 
system we also administered a polyclonal anti–IL-25 antibody (Figure 6.2).  Given our 
findings that IL-25 mediated inflammation was dexamethasone resistant, we 
hypothesized that IL-25 itself could be promoting T2M cells’ steroid–resistant 
phenotype.  Therefore, the inhibition of IL-25 may sensitize this population to high dose 
dexamethasone and reduce pulmonary type 2 inflammation.  As Figure 6.2a 
demonstrates, neither anti–IL-25 administration nor dexamethasone treatment altered Il4 
transcript expression in allergen–sensitized mice.  However, the administration of anti–
IL-25 in conjunction with dexamethasone resulted in a significant reduction in whole 
lung Il4 transcripts.  Given (as we have previously shown) that cytokine production in 
this model can be attributed to both T cell and T2M populations, these findings do not 
conclusively tie IL-25–dependent inflammation in this case to T2M cells.  Despite the 
absence of definitive data linking T2M cell–derived Il4 to changes in cytokine 
transcripts, the finding that anti-IL-25 administration significantly improved the anti-









Figure 6.2: Anti–IL-25 administration increases the anti-inflammatory effects of 
high dose dexamethasone treatment.  4get mice were sensitized to allergen as 
previously described, ± 0.5 mg anti-IL-25, ± 3 mg per kg dexamethasone.  Antibody was 
administered in 3 doses, on days 28, 30, and 32 post initial sensitization.  Dexamethasone 
was administered in 2 doses, prior to the intra-tracheal allergen challenge on days 30 and 
32.  (a-f) QPCR analysis of whole lung cytokine transcripts for Il4, Il5, Il13, Il17a, Ifng, 
and Il25, isolated 24 h post final allergen challenge.  Bars represent the mean ± s.e.m. of 
each group (n = 5). 
 
Transfer of T2M cells reconstitutes IL-25-induced airway responses 
In order to determine if IL-17RB+ T2M cells were sufficient to induce pulmonary 
inflammation, T2M cells from IL-25 treated mice were isolated and instilled into the 
airways of Il17rb–/– mice with recombinant IL-25.  The transfer of T2M cells from IL-25 
treated WT mice into Il17rb–/– recipients, coupled with instillations of IL-25, induced 
mucus production and inflammation in otherwise IL-25 insensitive Il17rb–/– animals (Fig. 
6.3).  Recipients of T2M cells also demonstrated significant increases Il13 transcripts, 
and the transfer of T2M cells with IL-25 further upregulated Il13 expression (Fig. 6.3b) 
as well as the mucus–specific gene Muc5ac (Fig. 6.3c).  In separate experiments, T2M 
transfer exacerbated the inflammatory response in WT recipients and increased Muc5ac 
transcripts to levels in Il17rb–/– recipients to levels comparable with those observed in IL-
25 treated WT animals (Fig. 6.4). A third set of similar experiments focused on T2M 
transfer in the context of allergic inflammation.  A similar pattern of increased mucus 
specific gene expression was observed following the adoptive transfer of T2M cells into 
allergen-sensitized recipients (Fig. 6.5).  Therefore, in the context of increased 
pulmonary IL-25 levels, T2M cells are sufficient to induce pulmonary inflammation, IL-




Figure 6.3: T2M cells are sufficient to induce airway pathology in Il17rb–/– mice.  (a) 
Representative histology from recipients of T2M transfer stained with PAS, 24 h post 
final IL-25 administration. Scale bar 400 µm; inset 100 µm.  T2M cells were isolated by 
MACS enrichment and FACS, and 2.0 x 105 cells were instilled into the airways of 
Il17rb–/– mice.  Mice received 4 total treatments, consisting of 0.5 µg IL-25, T2M cells 
alone, or IL-25 + T2M cells.  (b) QPCR expression of Il13 following T2M transfer (*P = 
0.017, #P = 0.042).  (c) QPCR expression for the mucus specific gene muc5ac (*P < 
0.026).  Bars represent the mean ± s.e.m. of 4 mice per group.  Results are representative 
of 3 independent experiments. 
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Figure 6.4: T2M adoptive transfer induces mucus production in IL-25 insensitive 
Il17rb–/– mice and exacerbates inflammation in WT recipients. FACS isolated T2M 
cells from the lungs of donor mice were treated with intra-tracheal IL-25. (a) Model used 
for T2M adoptive transfer (3.5x104 T2M cells per transfer) into either WT or Il17rb–/– 
recipients (n = 4 per group) . (b) Representative PAS stained histology from WT and 
Il17rb–/– mice. (c) mRNA analysis of lungs from recipient mice for the mucus gene 
Gob5, analyzed by QPCR.  Data represent the mean ± s.e.m. for each group, (*P < 0.05). 
(d) mRNA analysis of lungs from recipient mice for the mucus gene Muc5ac.  Data 
represent the mean ± s.e.m. for each group, (*P < 0.05). 
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Figure 6.5: T2M adoptive transfer increases mucus production in allergen sensitized 
recipients. (a) Model used for T2M adoptive transfer into allergen-sensitized recipients.  
Recipient 4get mice received 3 pulmonary allergen challenges and 2 adoptive transfers.  
(b) Representative PAS stained histology from allergen sensitized SHAM transfer and 
adoptive transfer recipients (scale bar top row 400 µm, bottom row 200 µm). (c) mRNA 
analysis of lungs of allergen sensitized 4get mice show significant increases in muc5ac 
transcripts following T2M adoptive transfer.  Data represent the mean ± s.e.m. for each 
group (n = 4 per group). 
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T2M–like cells are increased in asthmatics 
The above data establish T2M cells as contributors to type 2 inflammation and 
pulmonary pathology in mice, however they do not shed light on whether these cells are 
involved, or even present, in the context of human disease.  Our third experimental 
approach sought to address our lack of clinical data directly, through a clinical study of 
allergic asthmatics.  To investigate the potential correlation between T2M cells and 
clinically relevant disease, we investigated whether a similar population of IL-17RB 
expression granulocytes was present in humans.  Our initial experiments relied upon 
several suppositions, which could only be addressed through a direct assessment of 
clinical samples. 
The first of these suppositions was that an IL-25 responsive, bone marrow derived 
myeloid population must at some point traffic to the lung via peripheral circulation, and 
therefore could be detectable (if present) in a peripheral blood sample.  The fact that most 
asthmatic patients are on daily medications that effectively manage their symptoms and 
reduce the incidence of asthma attack somewhat complicated this point, as did an 
inability to know whether a T2M–like population, if even present in humans, would be 
released from the bone marrow at some detectable basal level or would only be produced 
upon a noxious stimulus or release of IL-25. 
Our second assumption was that a population analogous to T2M cells would 
express cell surface markers similar to those found in mice.  Human myeloid populations 
do not express markers analogous to either Gr-1 or F4/80, two of the antigens used to 
differentiate murine T2M cells from other myeloid subsets.  To address the lack of 
resolution resulting from this interspecies variation, we chose to evaluate peripheral 
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blood samples via flow cytometry by staining for surface antigens that could characterize 
IL-17RB+ subsets via the following parameters: 
1) Discriminate between lymphoid and myeloid IL-17RB+ populations. 
2) Distinguish myeloid cells as either monocytic or granulocytic. 
3) Identify type 2 cytokine production in IL-17RB+ subsets. 
4) Provide confirmation that a T2M–like population, if present, has similar 
expression patterns of those cell surface antigens shared between humans and mice. 
With these caveats in mind, volunteers were recruited from the University of 
Michigan Asthma Clinic, and the expression of IL-17RB in peripheral blood was 
compared to non-asthmatic volunteers.  While IL-17RB expression was either low or 
undetectable in non–asthmatic individuals, flow cytometric analysis identified 
significantly increased numbers of granulocytic IL-17RB+ cells in asthmatic patients 
(Fig. 6.6a, b).  The granulocytic IL-17RB+ population co-expressed CD11b, CD16, and 
the Ly6 family member/myeloid progenitor/neutrophil marker CD177269-271 (Fig. 6.6c).  
In addition, most IL-17RB+ cells were CD33+272, weakly expressed HLA-DR, and did not 
express the lymphocyte markers CD4 or CD8. 
Based on these findings, we focused our analysis upon IL-17RB+ CD11b+ CD16+ 
CD177+ cells and identified a significantly increased percentage of these cells in 
asthmatics (Fig. 6.7a) that was further elevated following in vitro stimulation with IL-25 
(Fig. 6.7b).  This IL-17RB+ subset produced both IL-4 and IL-13, whereas IL-17RB- 
cells with otherwise similar cell surface antigen expression did not.  Thus, a population 
with similar cell surface receptor expression and phenotype as murine T2M cells can be 
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identified in peripheral blood, is significantly elevated in asthmatics, and represents a 
source of both IL-4 and IL-13. 
 
 
Figure 6.6: Human IL-17RB+ granulocytes analogous to T2M cells are increased in 
asthmatics.  Granulocytes were isolated from peripheral blood samples donated by 
asthmatic (n = 9) or non-asthmatic (n = 8) volunteers and analyzed by flow cytometry.  
(a) Representative dot plots of granulocytes stained for IL-17RB, normalized to 400k 
events.  (b) Percent total IL-17RB+ granulocytes isolated from peripheral blood of 
volunteer donors.  Bars represent the mean ± s.e.m. for each group, (*P = 0.0031).  (c) 
Representative histograms of IL-17RB+ granulocytes from an asthmatic donor indicate 
the majority of IL-17RB+ granulocytes are CD11b+ CD16+ CD177+.  Cells were gated on 




Figure 6.7: Human T2M-like cells are a source of IL-4 and IL-13.  (a) Percent total 
CD11b+ CD16+ CD177+ IL-17RB+ granulocytes from volunteer donors. Bars represent 
the mean ± s.e.m. for each group, (*P = 0.023).  (b) Percent total CD11b+ CD16+ 
CD177+ IL-17RB+ cells from whole blood of volunteer asthmatic donors, cultured in 
vitro for 2 h ± 50 ng mL-1 IL-25.  (c) Representative intracellular cytokine staining for 




While current therapies effectively manage the symptoms of a majority of 
asthmatic individuals31, there is a significant subset of patients for whom corticosteroids, 
the most common medication used to suppress airway inflammation and the frequency of 
asthma attacks, remains ineffective34-36,163.  The possible mechanisms for steroid–
resistance are diverse and somewhat vague, in part because the exact cause is not fully 




Our data indicate that, based on the rapid accumulation of myeloid cells in lungs 
following IL-25 administration, there is a pool of cytokine producing IL-25 responsive 
cells capable of amplifying a type 2 response.  In allergic individuals, T2M cells may 
play an important role in the immediate response to an environmental allergen, priming 
the system for a type 2 response by producing cytokines prior to T lymphocyte activation.  
T2M cells could also contribute to chronic disease, as airway epithelial damage 
stimulates IL-25 secretion.  This concept may be especially relevant in asthmatics, as our 
studies identified increased numbers of T2M–like cells in the peripheral blood of 
asthmatics that may be recruited upon an exacerbation and accumulate in the lungs. The 
induction of IL-25 in airways by pathogens, allergens, or other noxious stimuli may 
amplify the severity of the response by activating steroid resistant T2M cells, especially 
in patients with underlying pulmonary disease. 
The fact that T2Ms are sufficient to induce mucus production, and that the 
adoptive transfer of T2Ms in the presence of IL-25 further exacerbates disease, provides 
strong evidence that these cells are pathologically relevant in environments with 
increased IL-25.  The exact mechanism by which T2M cells mediate their pro–
inflammatory effects has not been fully determined, however the significant upregulation 
of pulmonary Il13 in conjunction with their transfer offers evidence that T2M related 
pathology is driven, at least in part, by the secretion of IL-4 and IL-13. 
The identification of circulating T2M–like cells in asthmatics represents an 
extremely exciting finding, as it offers both evidence for the potential role of T2Ms in 
human disease as well as the potential for a relatively noninvasive measure of asthmatic 
pathology.  Clearly further study is needed, but characterization of the distribution of 
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T2M–like cells among a clinical population could represent a biomarker with some 
predictive value related to the quality of asthma symptom and a given patient’s likelihood 
of responding to specific therapies.  If IL-25 responsive granulocytes are truly associated 
with steroid-resistant disease, then management of those patients with high levels of 
T2M–like cells may be modified in order to reflect their underlying disease pathology. 
One could also image the utility of targeting such a population, perhaps by 
blocking the IL-25 receptor, in order to “sensitize” those IL-25 responsive cells and make 
them more prone to the effects of steroid.  In fact our data indicating that IL-25 can act as 
a sensitizing agent by reducing type 2 cytokine in conjunction with dexamethasone 
administration offers intriguing evidence for the potential clinical utility of targeting IL-
25 responsive populations in asthma.  A complete understanding of the development and 
function of T2M cells will require further investigation, however our findings identify 






Conclusions and Discussion 
 
 
Despite medicine’s long pursuit of effective treatment for asthma, to date there 
are no prophylactic or curative therapies available for what is generally a manageable but 
lifelong disease.  Many investigators have offered novel etiologies to explain the variety 
of intrinsic and extrinsic factors associated with its pathogenesis, as well is its variable 
clinical presentations.  These hypotheses have passed in and out of favor over time, as 
have their associated treatments.  Following the advent of psychoanalysis, for example, 
asthma was classified as one of the “holy seven” psychosomatic illnesses and thought by 
some physicians to reflect more about a patient’s emotional labiality than any underlying 
inflammatory process273.  For those practitioners who focused on asthma’s inflammatory 
etiology, therapies of the 20th century included “asthma cigarettes” (often laced with 
belladonna alkaloids, parasympathetic antagonists that inhibit bronchoconstriction), 
ephedra (later replaced in favor of epinephrine), and in the 1980s by inhaled β2 
adrenergic agonists such as albuterol274. 
The effectiveness of glucocorticoids in the treatment of asthma was first 
recognized in the 1950’s275, and marked a turning point in our understanding of the 
disease.  Subsequently, the “new” conventional wisdom was to view asthma as an 
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inflammatory condition, best treated by quenching the inflammatory response.  While 
this resulted in positive outcomes for many patients, after more than 50 years of use, 
medical practice has collectively come to appreciate the limitations of long-term steroid 
use, as well as the costs of indiscriminate immunosuppression.  Furthermore, while long-
term corticosteroids reduce the incidence of asthma exacerbations276, they do not improve 
lung function or modify underlying disease277.  The identification of steroid-resistant 
asthmatics further complicated the paradigm of asthma as a generalized inflammatory 
response, as certain individuals have severe disease that cannot be effectively managed 
with these drugs33-36,163.   
Discoveries in the last quarter century have unveiled dynamic regulatory 
mechanisms governing inflammatory responses, and offered the potential for targeted 
therapies that provide more effective symptomatic relief and fewer side effects for 
asthmatic individuals3.  A diverse array of helper T cell subsets have been identified, each 
with specific cytokine expression profiles related to responses required for the clearance 
of unique pathogens181.  In the past decade, innate immune cells have also been 
implicated in the production of these cytokines, and are now known to be critical 
mediators of type 2 inflammation required for the clearance of parasitic infections4,226,233.  
Innate immune populations produce cytokine in IL-25 and/or IL-33 dependent manners, 
thereby linking innate immunity with chemical signals released by the mucosal epithelia.  
Taken together, these findings have identified additional variables that must be 
considered, as part of a systemic response to pro-inflammatory stimuli such as 
environmental allergens, in order to develop treatments that target these previously 
unrecognized and pathologically relevant populations. 
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The initial objective of this research was to characterize the role of IL-25 in the 
pathogenesis of type 2 inflammatory responses resulting from chronic allergen exposure 
and RSV infection.  This was addressed in Chapters 3 and 4, in which we identified 
critical roles for IL-25 and its receptor, IL-17RB, in type 2 inflammatory responses 
induced during chronic allergic airways disease and RSV infection.  In the context of 
chronic allergic inflammation, both Th2 and IL-17RB+ myeloid cells acted as sources of 
type 2 cytokines.  Cytokine production in these cells was IL-25 dependent, and 
significantly reduced or absent in Il17rb–/– mice.  The establishment of systemic 
immunity required functional IL-25 receptors on CD4+ T cells, without which an 
effective antigen-specific response was not established. 
In Chapter 4, we identified IL-25 dependent responses in the mixed inflammatory 
reaction resulting from RSV infection.  IL-25 played a critical role in the immune 
response to RSV, particularly with respect to IL-13 mediated mucus hypersecretion.  IL-
25 blockade, or loss of a functional IL-25 receptor, significantly reduced type 2 cytokine 
production and RSV–associated pathology.  The exacerbation of underlying allergic 
disease by RSV infection further increased type 2 cytokines in an IL-25 dependent 
manner; therefore IL-25 plays a role in both RSV pathogenesis and the viral exacerbation 
of allergic disease.  Il17rb–/– mice exposed to allergen, RSV infection, or both exhibited a 
significant reduction in airway pathology and type 2 cytokine production, thereby 
providing additional evidence for the pathologic relevance of IL-25 in these diseases. 
In sum, the data presented in Chapters 3 and 4 emphasize the importance of IL-25 
as a regulator of type 2 immunity.  It is a cytokine that influences the biology of multiple 
cell types, enhances antigen-specific responses, and can promote type 2 inflammation de 
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novo.  However the biologic function of IL-25 is not solely to promote a type 2 response; 
it is potent regulator of inflammation at the mucosal epithelia, and insensitivity to IL-25-
dependent signals does not simply reduce type 2 responses.  IL-25 blockade releases an 
inhibitory signal, resulting in significant increases in Th1 and Th17 cytokine production 
in mixed inflammatory environments (Chapter 4).  While this phenomenon has not been 
previously reported in the context of pulmonary infection, the importance of IL-25 in the 
maintenance of intestinal inflammatory homeostasis was recognized by Zaph et al.208.  
The role of IL-25 in the development and maintenance of immune tolerance sheds some 
light on the important counterregulatory function of type 2 immunity in maintaining 
balance in immunologically active tissues.  Commensal bacteria stimulate IL-25 
production in the intestinal mucosa, and in so doing suppress production of IL-17A and 
IL-23.  Conversely, IL-25 is not produced by the intestinal epithelium of germ free mice, 
resulting in an overproduction of IL-17A and IL-23, which can be suppressed via 
exogenous IL-25 administration.  While these findings do not directly demonstrate the 
pathologic relevance of IL-25 as an inhibitor of Th17-associated signals, subsequent 
reports have indicated a counterregulatory role for IL-25 in the inhibition of both type 
1198 and type 17 inflammation209,246, with recent studies focusing on the inverse 
relationship between IL-17A and IL-25 mediated pulmonary pathology201,278.  The 
counterbalancing effect of IL-17A and IL-25 was certainly one component of the 
inflammatory response observed in Il17rb–/– animals following RSV infection, in which 
LN restimulation resulted in a dramatic increase in both IFNγ and IL-17A. 
The findings presented in Chapter 4 offer important insight into how to 
therapeutically target IL-25-dependent pathologies.  The contribution of multiple cell 
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subsets to type 2 immunity foreshadows potential difficulties involved in designing 
therapies to abrogate effects of a system with redundancies in both the function of 
chemical signals and the cellular sources of those signals.  Type 2 immunity requires this 
level of complexity to thwart multiple mechanisms a pathogen may use to evade immune 
recognition and/or activation.  It is only through an understanding of these regulatory 
motifs that we will be able to effectively target processes at multiple levels of regulation. 
Clinically, the most severe sequela of both allergic asthma and RSV infection 
results from airway obstruction and subsequent ventilation-perfusion mismatch.  Type 2 
cytokines, IL-13 in particular, act as primary mediators of mucus hypersecretion in both 
asthma and RSV infection153,157,247.  IL-25’s ability to promote cytokine production was 
therefore of great interest because IL-13 has been identified as the type 2 cytokine most 
closely associated with poor clinical outcomes.  The role of IL-25 in other respiratory 
viral infections such as influenza and rhinovirus remains to be determined.  The mixed 
inflammatory environment associated with viral exacerbations could be modulated in part 
by IL-25-dependent processes.  Any agent, infectious or otherwise, which increases the 
level of baseline inflammation may bring an asthmatic individual closer to their “tipping 
point” and an asthma exacerbation.  A greater understanding of IL-25’s role in various 
viral infections will provide valuable insight as to how best to treat the symptoms of viral 
exacerbation.  
Upstream regulators of heterogeneous, chemokine-dependent inflammatory 
processes such as IL-17A and IL-25 offer intriguing targets for the inhibition of signals 
required for the recruitment of allergen–induced effector populations. Allergen–induced 
inflammatory responses, and inflammation associated with viral exacerbations of existing 
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pulmonary disease, are significantly reduced when either the ligands or receptors for both 
IL-17A and IL-25 are blocked16,117,193,213.  IL-17A induces CXCL1, CXCL8, CCL20 
(MIP-3α), and IL-6207, and its blockade inhibits the production of these mediators, 
preventing the influx of lymphocytes and neutrophils, and causing a blunted 
inflammatory response279.  Likewise, the blockade of IL-25 decreases Th2 inflammation 
by reducing IL-4 and IL-13 and thus the production of Th2-induced chemokines CCL11 
(Eotaxin) and CCL17 (TARC).  By blocking IL-17A and IL-25 in tandem, it may be 
possible to prevent the counterregulatory swing observed following the inhibition of IL-
25 alone. 
A recent study has exploited the similarities in IL-17A and IL-25 signaling to 
engineer a peptide that blocks signal transduction by both cytokines.  As has been 
discussed previously, IL-17A and IL-25 require Act1 and TRAF6 dependent interactions 
to induce downstream NFκB activation202-205,214,280.  Liu et al. reported that a CC loop 
mimetic of the Act1 SEFIR domain effectively blocked interactions between Act1 and 
the IL-17A and IL-25 receptors254.  It reduced phosphorylation of downstream kinases, as 
well as transcripts of cytokine-dependent genes such as Cxcl1 and Il13 by 50% and 60%, 
respectively.  These findings offer a peptidomimetic-based strategy to effectively target 
cytokines with oppositional actions, one that may also enable the development of 
receptor-specific peptides in cases where the abrogation of IL-17 or IL-25 signals would 
not be advantageous254. 
In Chapter 5, we employed an antigen-independent model of IL-25-mediated 
inflammation to identify a novel granulocytic population, termed T2M cells.  The initial 
hypothesis for this work was that an IL-25–responsive myeloid population contributed to 
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type 2 immunopathology in the lung.  This was based in large part on previous findings 
from our lab and others that bone marrow–derived cytokine producing populations were 
important contributors to type 2 inflammatory responses, specifically in the context of 
chronic allergic inflammation (Chapter 3)11,225.  Through comprehensive 
characterization of IL-25 responsive myeloid populations, T2M cells were identified as a 
novel granulocytic population of innate IL-25 responsive cells involved in the 
pathogenesis of allergic asthma.  T2Ms produce IL-4 and IL-13, and are recruited in large 
numbers to the lung in response to IL-25 secretion.  They exhibit a distinct morphology, a 
unique pattern of cell–surface antigen expression, as well as a microarray expression 
profile distinct from other myeloid subsets. 
One question raised by these findings is why are there multiple innate cytokine 
producing populations when the adaptive immune response functions to produce those 
same cytokines?  Neutrophils, for example, can produce both IL-17A281 and IFNγ282 in 
certain contexts, and we have previously discussed the many cell types capable of IL-4 
secretion.  The answer may lie in the importance of these signals at multiple stages of the 
inflammatory response, as well as in the conservation of evolutionarily important 
inflammatory mechanisms.  Cytokine production from innate lymphoid cells234, 
eosinophils268,283, basophils258, NK cells216, and, as this thesis describes, T2M cells, plays 
a critical role in the appropriate function of mucosal immunity.  Redundancies in 
cytokine production serve as reminders of the system’s evolutionary history as well as its 
importance, as innate cytokine production is required for helminth clearance while 
adaptive immunity is dispensable226.  Prior to the evolution of adaptive immunity, innate 
immune populations relied upon similar cytokine signals to coordinate an appropriate 
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inflammatory response.  This concept is supported by phylogenetic analysis of immune 
populations in a range of animal species.  The IL-17 family, for example, is 
evolutionarily conserved and plays a critical role in agnathan (hagfish and lamprey) 
immunity284.  These primitive, jawless vertebrates rely upon a thick layer of mucus as 
their primary barrier against environmental pathogens, and coordinate inflammatory 
responses with an IL-17 family member resembling IL-17D284.  Depending on context, it 
may be that innate populations produce cytokine to effect a reaction while the adaptive 
response is being established.  As the studies described in this thesis indicate, cytokine 
production by T2M cells may contribute to the enhancement or maintenance of chronic 
inflammation by promoting mucus production. 
Another question raised is whether T2M cells represent a terminally differentiated 
subset.  Their morphology suggests an immature or progenitor phenotype, yet microarray 
analysis indicates that they are most closely associated with eosinophils, despite differing 
in expression from eosinophils at several thousand loci.  T2Ms are not mature 
eosinophils: they do not express CCR3 or IL-5rα, nor did FACS sorted T2Ms express 
transcripts of eosinophil peroxidase or major basic protein, both of which are linked to 
mature eosinophil function.  Interestingly, both CCR3 and IL-5rα mRNA were enriched 
in T2M cells upon microarray analysis.  Eosinophils and their progenitors express IL-5rα 
prior to migrating from the bone marrow144,255.  CCR3 expression is required for 
chemotaxis to inflammatory sites, and is upregulated following IL-5 exposure146,149. T2M 
differentiation into eosinophils, neutrophils or basophils, would require extramedullary 
terminal differentiation by an as yet unknown mechanism. 
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The most straightforward way to test whether T2Ms are capable of differentiation 
into another cell type would involve culturing T2Ms in a variety of cytokine cocktails 
that promote differentiation of the various myeloid subsets, and then assessing for altered 
cell surface marker expression and cell-type specific products.  For example, murine 
eosinophils can be derived by culture of whole bone marrow with SCF and Flt3 ligand, 
followed by culture with IL-5285.  The derivation of eosinophils from in vitro T2M 
cultures would demonstrate that T2Ms are not terminally differentiated.  Table 7.1 lists 
examples of culture conditions that have been used for the in vitro generation of 
eosinophils, basophils, and neutrophils. 
 
Desired cell type 
Cytokine combination 
reported to drive 
differentiation from 
progenitors in vitro 
Cell-surface markers 
used to define subset Cellular products 
    
Eosinophil SCF, Flt3 (days 1-4), IL-5 days 5-8285 IL-5rα, CCR3 
Eosinophil peroxidase, 
major basic protein, 
eosinophil cationic 
protein 
Basophil GM-CSF, SCF, IL-3, anti-IL-5256 IL-3r, FcεR1, CD49b Histamine 
Neutrophil G-CSF, SCF, Flt3 ligand286 CXCR2 Myeloperoxidase 
 
Table 7.1: Potential culture conditions to stimulate granulocyte maturation and 
differentiation in T2M cells.256,285,286 
 
 
While these experiments appear straightforward, initial attempts to characterize 
T2M biology in vitro have been hampered by their granulocytic nature.  Even when 
cultured in Teflon plates, T2M cells isolated by FACS aggregate en masse, likely as a 
result of adhesion molecule activation.  This presents a somewhat difficult problem, in 
that the isolation of T2M cells requires the induction of IL-25 associated inflammation, 
however IL-25 promotes type 2 cytokine production in T2Ms.  Therefore IL-25 acts as an 
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activating signal and may itself be responsible for adhesion molecule activation in these 
cells.  Experiments employing different culture conditions, including changes to plated 
cell density or perhaps the use of specific media, may be required to enable the effective 
study of T2Ms in vitro. 
Our data indicate that T2M cells do not actively proliferate in target tissues such 
as lung (Chapter 5). Therefore, the differentiation of T2M cells into another subset 
would require a metamorphosis of both phenotype and biological function from T2Ms to 
a terminally differentiated population.  This seems an unlikely scenario, and to date we 
have no data to suggest that this is the case.  It is more likely that T2Ms share a common 
progenitor with the other granulocytes.  However, the absence of IL-5rα144,255 and 
FcεR1256 implies that T2M cells are not members of committed eosinophil or basophil 
subsets.  One possibility is that exposure to an activating signal, perhaps IL-25 itself or 
IL-25 in concert with SCF, may promote T2M differentiation instead of the fate normally 
assumed by a common progenitor population, thereby altering the pattern of 
differentiation those myeloid progenitors would otherwise undergo.  This concept is 
logical, as previous studies from our laboratory have demonstrated that the induction of 
IL-25 by SCF during chronic allergen challenge is a requirement for the generation of IL-
4 producing myeloid cells in the bone marrow11.  In separate experiments, mice deficient 
in the SCF receptor c-kit exhibited equivalent inflammatory responses to WT mice when 
challenged with IL-25 (data not shown).  Taken together, these findings suggest that 
while the production of IL-25 requires c-kit, T2M cell differentiation may be c-kit 
independent. Although experiments investigating the origins of T2M cells are in their 
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infancy, identifying the parent population of T2M cells will offer an alternative approach 
to investigate their differentiation.   
Our final set of experiments explored the pathological significance of T2M cells 
(Chapter 6).  T2M adoptive transfer generated IL-25–associated immunopathology in 
the airway.  High dose dexamethasone administration, the front line therapy for allergic 
asthma exacerbations, did not reduce cytokine production in, or total numbers of, T2M 
cells.  These findings indicated that T2Ms are sufficient to induce clinically relevant IL-
25–mediated pathology.  However, it was the identification of an analogous human 
population of T2M-like cells in peripheral blood of atopic asthmatics that offered the 
most powerful evidence in support of T2Ms as a clinically relevant population.  T2M–
like cells were identified in 9 out of 9 asthmatic subjects, and were either absent or 
present at significantly lower levels in non–atopic individuals (see Figure 6.7).  Similar 
to the population identified in mice, these human T2M-like granulocytes were IL-17RB+, 
responded to IL-25, and produced IL-4 and IL-13. Based on these data, the identification 
of a novel and pathologically relevant granulocytic subset offers an important new 
avenue of research investigation with the potential for significant translational impact. 
What are the mechanisms by which T2M cells function as a pathologically 
relevant population?  Specifically, how do T2M cells resist glucocorticoid–mediated 
apoptosis and promote type 2 inflammation?  The mechanisms of steroid resistance in 
inflammatory populations are diverse and not fully understood33,34,36.  Glucocorticoid 
(GC) suppresses inflammation by three main mechanisms.  The first involves binding of 
GC to the glucocorticoid receptor (GR) in the cytosol, which translocates to the nucleus 
and can bind directly to GC response elements (GREs) to upregulate target genes such as 
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the anti–inflammatory cytokine IL-10287.  An activated GR can also bind directly to 
transcription factors such as NFκB and suppress downstream activation of target 
cytokines288.  The third major mechanism of GC action involves a pro-apoptotic 
response.  GCs can induce apoptosis directly through a bax-dependent mechanism, in 
which cytochrome c is released from the mitochondria and activates caspases in the 
cytosol289.  In asthmatics, GC resistance among lymphocyte populations has been linked 
to increased expression of IL-2 and IL-4290, and patients with steroid–resistant asthma 
have significantly increased serum IL-432.  These cytokines reduce binding affinity and T 
cell responsiveness to GCs, however the precise mechanism for this effect is unknown.  
As Le et al. summarize, 
GC resistance in asthma cannot [sic] be explained by malabsorption, 
pharmacokinetic mechanisms, defects in the binding of steroids to cytosolic 
glucocorticoid receptors, nor by defective nuclear translocation of this receptor.  
This implies that the major mechanisms for GC resistance occur distal to the 
nuclear translocation step291. 
 
In in vitro experiments with CD4+ T cells skewed toward a Th2 or Th17 phenotype, 
McKinley et al. demonstrated that Th17 cells are resistant to steroid, despite nuclear 
translocation of the GR161.  The adoptive transfer of Th17 cells was sufficient to induce 
GC resistant airway hyperreactivity, supporting the hypothesis that specific cytokines (in 
this case IL-17A) may play a role in the development of GC resistance.  Cytokine-
mediated steroid-resistance may represent a mechanism by which T2M cells maintain 
resistance to GCs, and is supported in part by findings that IL-17A increases production 
of the GC receptor beta in the airway epithelial cells of asthmatics292.  GC beta cannot 
bind glucocorticoids, thus it acts in a dominant-negative manner to inhibit normal GC 
signaling through GC receptor alpha292. 
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An interesting parallel to our finding that T2M cells are resistant to steroids, as 
well as a potential mechanism to explain T2M steroid-resistance, can be drawn from the 
findings of a group studying malignant breast cancers293.  These investigators identified 
tumors that are exquisitely sensitive to IL-25.  IL-17RB binding promotes apoptosis in 
breast cancer cells but not normal breast tissue, and IL-25 is now being pursued as a 
possible therapeutic agent for IL-17RB+ tumors.  As part of the investigation into the 
mechanism of IL-25-mediated apoptosis, IL-17RB’s TRAF6 binding site was mutated to 
prevent TRAF6 interaction.  Surprisingly, TRAF6 mutations made cells even more 
sensitive to apoptosis, indicating that TRAF6 binding to IL-17RB acts as an anti-
apoptotic signal.  Although these experiments were conducted in completely different 
cells and experimental conditions, the results of these experiments indicate that activation 
of NFκB via TRAF6 (the mechanism by which IL-25 induces the expression of type 2 
cytokines) can act as a pro-survival signal.  As previously discussed, GCs promote 
apoptosis via bax-dependent caspase activation289.  Therefore, in the context of IL-25 
mediated inflammation, IL-25-IL-17RB interactions alone may serve to protect T2M 
cells from apoptotic responses by inhibiting GC mediated caspase activation.  Although 
we have not investigated this hypothesis, our finding that the administration of an anti-IL-
25 antibody in allergen-sensitized mice significantly increased the anti-inflammatory 
effects of dexamethasone offers some circumstantial evidence that may corroborate an 
IL-25–dependent pro–survival effect (see Figure 6.2).  Future studies to further 
characterize T2M cells should include an investigation of the mechanism underlying GC 
resistance in this population. 
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Several questions remain regarding the biologic and pathogenic mechanisms of 
T2M function.  The most consistent T2M–associated pathology involves goblet cell 
hypertrophy and mucus hypersecretion.  These actions are most likely driven by IL-13, as 
it is both produced by T2Ms and intimately associated with increased mucus 
production153.  We have not explored other potential mechanisms for T2M–mediated 
pathology, however several other groups have associated so–called “myeloid suppressor” 
(CD11b+ Gr-1mid) cells with anti–inflammatory effects dependent upon the production of 
nitric oxide and superoxide243,244.  A recent study identified three populations of myeloid 
suppressor cells in a model of allergic asthma, characterized according to Ly6G and 
Ly6C expression294.  These populations mediated cytotoxic effects via NO and 
superoxide production (depending on the cell type).  However, the model used by these 
investigators did not generate sufficient numbers of these Ly6C+ Ly6G+ F4/80+ cells 
(similar by surface marker to T2Ms) to investigate their production of reactive oxygen 
species, so their mechanism of action remains unknown.  Based on their anti-
inflammatory properties, it may be that myeloid suppression described in these 
investigators relates to the biological function of the IL-17RB+ Gr-1hi myeloid population 
we identified that did not produce IL-4 or IL-13 (see Figure 3.4). 
 The biological activity of Gr-1hi myeloid cells has not been investigated beyond 
their initial characterization as a separate CD11b+ IL-17RB+ subset.  This population is 
significantly increased in allergic asthma and present in similar numbers to T2M cells, 
however unlike T2Ms this population does not produce type 2 cytokines (Chapter 3).  
Similar findings were observed in our antigen–independent model of type 2 
inflammation, where 50% of the IL-17RB+ myeloid population also expressed GFP/IL-4 
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(Chapter 5).  It would be interesting to determine whether the 50% lacking GFP 
expression has some immunomodulatory function related to T2M biology, if these cells 
contribute significantly to disease, and whether they are modulated in some manner by 
IL-25. 
Further investigation of T2M origins, and the cellular signals regulating T2M 
biology, may also add substantially to our understanding of innate immunity and IL-25 
dependent biological processes.  For example, the feedback mechanism(s) required for 
T2M induction in the bone marrow has not been fully determined.  While we have 
previously identified an SCF–dependent mechanism of myeloid cell recruitment to the 
allergic lung11, it remains to be seen whether IL-25 acts exclusively on T2M cells through 
an SCF-dependent mechanism, or if other signals are required for T2M development.  
The distribution of T2M cells in the lung parenchyma versus the airway has not been 
fully characterized, nor has how inflammatory stimuli or chemotactic agents may affect 
the distribution of these cells.  It would also be interesting to investigate whether T2M 
cells are present in the gastrointestinal tract in addition to hematopoietic and lung tissue.  
Innate lymphoid populations do not appear to increase in the lung, so perhaps certain 
innate populations respond preferentially to inflammatory signals from intestinal or 
pulmonary epithelia.  One possible explanation is that T2M cells do not express the IL-33 
receptor, whereas innate lymphoid populations have been found to be four to six times 
more sensitive to IL-33 than to IL-2523,235.  Perhaps innate lymphoid cell recruitment 
requires a strong IL-33 stimulus that is lacking in both allergic asthma and RSV 
infection, but present in the context of infection with intestinal helminthes295. 
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The identification of a human T2M homologue is the most intriguing, and in time 
may be the most meaningful, contribution made by this thesis.  Our initial findings 
indicate that the presence or absence of T2M-like cells is related directly to the symptoms 
of moderate to severe atopic asthma.  The identification of these cells in the peripheral 
circulation of asthmatic individuals is extremely exciting as it offers a minimally invasive 
test that may have significant predictive value.  By contributing an additional parameter 
through which asthmatic patients could be stratified in the future, the identification of this 
population presents a variety of questions that will require further investigation. 
The clinical impact of T2M cells can be classified according to potential 
prognostic and therapeutic utility.  For example, evaluating a larger patient population for 
the presence of IL-17RB+ granulocytes may make it possible to correlate numbers of 
circulating cells with demographic data, including age, sex, exposure history to various 
allergens, urban versus rural habitation, clinical symptoms, family history, medical 
comorbidities, and drug response profiles.  Further study may enable the stratification of 
an individual’s disease severity based on their unique profile of T2M–like cells, and 
could be particularly useful in individuals with steroid–resistant disease.  Further study 
may also provide some predictive value as to how an individual may react to specific 
pharmacotherapy, or enable monitoring of the effectiveness of a treatment protocol, 
particularly related to patients with steroid-resistant asthma. 
The ability to readily assess and quantify this circulating population also offers 
the potential for the use of these cells as a biomarker for disease pathogenesis.  For 
example, measuring numbers of circulating T2M–like cells in an individual when asthma 
is well–controlled, versus during IL-25 associated events such as a viral exacerbations or 
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bronchospasm following allergen exposure, could offer insight into how these cells relate 
to clinical pathology or aid in the prediction of an impending exacerbation.  Finally, 
while we have identified T2M cells and their human homologue in the context of allergic 
asthma, we have not investigated whether these cells are present in, or contribute to, a 
myriad of other conditions associated with type 2 immune responses.  These may include 
diseases of epithelial tissues such as atopic dermatitis173,220, hypereosinophilic syndromes 
such as Eosinophilic Esophagitis263, and autoimmune disorders such as Churg-Strauss 
syndrome14,264.  Our findings offer a framework for future investigators interested in 
these and other questions related to IL-25 biology, innate immunity, and novel targets for 
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